<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://adc.bmj.com">
<title>ADC Online First</title>
<link>http://adc.bmj.com</link>
<description>ADC RSS Feed -- Online First</description>
<prism:eIssn>1468-2044</prism:eIssn>
<prism:publicationName>Archives of Disease in Childhood</prism:publicationName>
<prism:issn>0003-9888</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301212v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301789v2?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301457v2?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301684v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301648v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301938v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301631v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300651v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301093v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301326v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301501v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301794v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301719v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301989v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300806v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300829v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300272v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301496v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300853v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300653v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301476v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301864v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300305v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301561v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301150v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301810v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301696v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301284v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301229v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301089v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301299v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301253v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2012-301731v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2012.301776v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301236v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301175v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301239v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300646v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300538v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301604v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300854v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301295v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild.2011.301180v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300221v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301163v2?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301458v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301327v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300667v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300770v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301308v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-301248v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300120v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300603v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2010.202069v2?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/archdischild-2011-300294v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2010.195180v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2010.206268v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2010.198275v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2010.206201v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2010.189639v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2010.186429v1?rss=1" />
  <rdf:li rdf:resource="http://adc.bmj.com/cgi/content/short/adc.2009.160853v1?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.adc.bmj.com/misc/home/ADC_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.adc.bmj.com/misc/home/ADC_95x60.gif">
<title>Archives of Disease in Childhood</title>
<url>http://hwmaint.adc.bmj.com/misc/home/ADC_95x60.gif</url>
<link>http://adc.bmj.com</link>
</image>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301212v1?rss=1">
<title><![CDATA[Inpatient care for children with diabetes: are standards being met?]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301212v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Hospital inpatient care is frequently mentioned by parents as unsatisfactory for children with diabetes. Ward staff are now less familiar with diabetes, as admissions are less common and diabetes management is more intensive.</p></sec><sec><st>Objective</st><p>To compare current practice with Department of Health Children's Diabetes Working Group care standards.</p></sec><sec><st>Methods</st><p>This audit surveyed the organisation of inpatient care for children with diabetes in three regional networks in southern England, and was funded by the Healthcare Quality Improvement Partnership.</p></sec><sec><st>Results</st><p>All 27 services completed the questionnaire. Protocols for diabetic ketoacidosis, surgery, new diagnosis and hypoglycaemia were generally available on wards (70% had all four protocols) but less available in emergency departments (EDs) (52%). Trained children's nurses worked on every shift in children's wards (100%) but not necessarily in EDs (33%). Diabetes link nurses were identified on 74% of wards and 61% of high-dependency units (HDUs), and diabetes specialist nurses have inpatient liaison in their job description (89%) and working role (93%). Standards achieved less often were access to dietetic advice on wards (37%), education sessions for ED and ward staff, and informing diabetes team (only 26% within 2 h of admission during the day, and only 11% would contact the diabetes consultant overnight for a child admitted to a paediatric intensive care unit/HDU). Half of centres reported insulin errors.</p></sec><sec><st>Conclusions</st><p>This first audit of children's diabetes inpatient care organisation demonstrates that some standards can be achieved, but others, such as having children's nurses on every shift in EDs, lack of dietetic advice to ward staff, and liaison with the diabetes team quickly out of hours, are more challenging. Further planned audit outcomes are to produce patient and parent literature for children admitted to hospital and to refine the standards further.</p></sec>]]></description>
<dc:creator><![CDATA[Edge, J., Ackland, F. M., Payne, S., McAuley, A., Hind, E., Burren, C., Burditt, J., Sims, D.]]></dc:creator>
<dc:date>2012-05-10T02:01:04-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301212</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301212</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Child health, Neonatal and paediatric intensive care, Paediatric intensive care, Diabetes, Metabolic disorders]]></dc:subject>
<dc:title><![CDATA[Inpatient care for children with diabetes: are standards being met?]]></dc:title>
<prism:publicationDate>2012-05-10</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301789v2?rss=1">
<title><![CDATA[The first images of varicella lesions in the bladder]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301789v2?rss=1</link>
<description><![CDATA[<p>A 3-year-old boy with a recurrent prolapsing vesicostomy presented with multiple lesions over his prolapsed bladder mucosa <cross-ref type="fig" refid="F1">figure 1</cross-ref>. He had recently contracted varicella, and had developed characteristic &lsquo;chickenpox&rsquo; lesions over his torso. The lesions on his bladder were of similar appearance and it was felt that the varicella was the likely cause as the virus can sometimes affect mucosal membranes. The bladder lesions resolved over the same course of time as those elsewhere.</p><p>Primary infection with the varicella zoster virus, is characterised by a rash, often accompanied by fever and malaise, which starts as macules, then progresses rapidly through papular and vesicular stages, before crusting over. Skin manifestations are the most common, but it can also affect the mucosa of the conjunctivae, oropharynx and introitus of the genitourinary tract.<cross-ref type="bib" refid="R1">1</cross-ref></p><p>Varicella affecting bladder mucosa, is rarely reported. A single case report describes a child with varicella affecting skin...]]></description>
<dc:creator><![CDATA[Holbrook, C. M., Waller, S.]]></dc:creator>
<dc:date>2012-05-07T11:13:50-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301789</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301789</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Surgery, Urology, Journalology, Ophthalmology, Dermatology, Surgical diagnostic tests, Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[The first images of varicella lesions in the bladder]]></dc:title>
<prism:publicationDate>2012-05-07</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301457v2?rss=1">
<title><![CDATA[Active surveillance of serious adverse drug reactions in New Zealand children]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301457v2?rss=1</link>
<description><![CDATA[<p>Children are at risk of developing adverse drug reactions (ADRs),<cross-ref type="bib" refid="R1">1</cross-ref> yet few are reported through postmarketing surveillance schemes monitoring safety in this vulnerable population.<cross-ref type="bib" refid="R2">2</cross-ref> We therefore developed an active surveillance system targeting New Zealand paediatricians to enhance serious ADR notifications in children aged &lt;16 years.</p><p>A priori, paediatricians were given written case definitions of serious ADRs, which they then notified to the New Zealand Paediatric Surveillance Unit (NZPSU) using standard methodologies described elsewhere.<cross-ref type="bib" refid="R3">3</cross-ref> Cases were defined as noxious and unintended responses associated with the use of prescription, non-prescription and complementary medicines at any dose and resulting in hospitalisation or an Emergency Department visit, prolongation of hospitalisation, persistent or significant disability, or death in children aged &lt;16 years. Reactions to vaccines, blood products, medical devices, poisonings or self-administered overdoses were excluded. The New Zealand Health and Disability Multi-region Ethics Committee approved the study.</p><p>During the 3-year period...]]></description>
<dc:creator><![CDATA[Kunac, D., Tatley, M. V., Grimwood, K., Reith, D. M.]]></dc:creator>
<dc:date>2012-05-07T11:13:51-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301457</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301457</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Active surveillance of serious adverse drug reactions in New Zealand children]]></dc:title>
<prism:publicationDate>2012-05-07</prism:publicationDate>
<prism:section>Letter</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301684v1?rss=1">
<title><![CDATA[Chickenpox in the immunocompromised child]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301684v1?rss=1</link>
<description><![CDATA[<p>For the majority of children who are immunocompromised or who require immunosuppression, their primary diagnosis necessitates a difficult programme of prolonged treatment. In countries with no varicella vaccination, this is compounded by the ever-present and significant threat of chickenpox. Potential exposures must be avoided, causing children to miss school and playgroups whenever chickenpox is at large. Each contact with varicella results in negotiating blood testing to assess their current varicella zoster virus (VZV) status followed by either varicella zoster immunoglobulin (VZIG) therapy or antiviral treatment in hospital or five times a day at home. Immunosuppressive treatment may be interrupted with consequent risk of reduced remission rates, or disease relapse.</p><p>Before the availability of VZIG and antiviral agents, the death rate from varicella was around 7% for children being treated for cancer, with 32% having visceral dissemination; children with lymphopenia were at highest risk.<cross-ref type="bib" refid="R1">1</cross-ref> Since the use of prophylaxis and...]]></description>
<dc:creator><![CDATA[Roderick, M., Finn, A., A V, R.]]></dc:creator>
<dc:date>2012-05-04T02:01:26-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301684</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301684</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Liver disease, Immunology (including allergy), Drugs: infectious diseases, Hepatitis and other GI infections, HIV/AIDS, Pneumonia (infectious disease), TB and other respiratory infections, Vaccination / immunisation, Infection (neurology), Child health, Pneumonia (respiratory medicine), Sexual health]]></dc:subject>
<dc:title><![CDATA[Chickenpox in the immunocompromised child]]></dc:title>
<prism:publicationDate>2012-05-04</prism:publicationDate>
<prism:section>Leading article</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301648v1?rss=1">
<title><![CDATA[Child abuse and its legislation: the global picture]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301648v1?rss=1</link>
<description><![CDATA[<p>Amid the high income nations the first recognisable child abuse society was founded in the late 19th century in North America, but it was a century before the first global rights-based legislation in the form of the United Nations Convention on the Rights of the Child (UNCRC) came into play. In isolation, international legislation is insufficient to protect children but becoming party to international law sends a clear signal to the community and stakeholders that a country is committed to ensuring child protection. Incorporating and implementing the UNCRC and other child protection based legislation on a global scale is not without difficulty and there are many obstacles to fulfilling its principles and monitoring its progress. The author reviews the global pandemic of violence against children and provides an overview of the legislation that has evolved over the last century in response to it. The author also seeks to examine some of the practical difficulties and limitations in implementing global child abuse legislation with reference to three important areas: the prohibition of violence, professional capacity enhancement, and data collection and research. The role of the paediatrician is also discussed in applying a rights-based approach to promoting global child protection.</p>]]></description>
<dc:creator><![CDATA[Cutland, M.]]></dc:creator>
<dc:date>2012-05-04T02:01:25-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301648</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301648</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Child abuse, Abuse (child, partner, elder)]]></dc:subject>
<dc:title><![CDATA[Child abuse and its legislation: the global picture]]></dc:title>
<prism:publicationDate>2012-05-04</prism:publicationDate>
<prism:section>Global child health</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301938v1?rss=1">
<title><![CDATA[Long-term consequences of neonatal mastitis]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301938v1?rss=1</link>
<description><![CDATA[<p>Neonatal mastitis is an uncommon condition that occurs in full term infants in the first few weeks of life. Girls are affected twice as often as boys. Initial management consists of intravenous antibiotics, while in cases of abscess formation, incision and drainage is indicated.<cross-ref type="bib" refid="R1">1</cross-ref> Data on the long-term outcomes of neonatal mastitis are scarce. We aimed to examine whether mastitis in infancy affects consequent breast development in girls. The case notes of all peri-pubertal girls, who had been treated as infants for neonatal mastitis 10&ndash;15 years previously at a single institution, were reviewed retrospectively. Demographics, clinical findings, management and outcomes were recorded. Ten patients were identified; the families were contacted and patients were asked to return for clinical review and breast ultrasound. Eight girls attended follow up at a median age of 14 years (range 10&ndash;15 years). At the time of review, seven girls were post-pubertal while one...]]></description>
<dc:creator><![CDATA[Panteli, C., Arvaniti, M., Zavitsanakis, A.]]></dc:creator>
<dc:date>2012-05-01T02:03:49-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301938</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301938</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Long-term consequences of neonatal mastitis]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301631v1?rss=1">
<title><![CDATA[20 mm lithium button battery causing an oesophageal perforation in a toddler: lessons in diagnosis and treatment]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301631v1?rss=1</link>
<description><![CDATA[<p>Swallowed button batteries (BB) which remain lodged in the oesophagus are at risk of serious complications, particularly in young children. The authors report a 3-year-old child, who rapidly developed an oesophageal perforation, following the ingestion of a 20-mm lithium BB which was initially mistaken for a coin. A thoracotomy and T-tube management of the perforation led to a positive outcome. BBs (20 mm) in children should be removed quickly and close observation is required as the damage initiated by the battery can lead to a significant injury within a few hours.</p>]]></description>
<dc:creator><![CDATA[Soccorso, G., Grossman, O., Martinelli, M., Marven, S. S., Patel, K., Thomson, M., Roberts, J. P.]]></dc:creator>
<dc:date>2012-05-01T02:03:48-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301631</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301631</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oesophagus, Drugs: psychiatry, Trauma, Injury]]></dc:subject>
<dc:title><![CDATA[20 mm lithium button battery causing an oesophageal perforation in a toddler: lessons in diagnosis and treatment]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Case report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300651v1?rss=1">
<title><![CDATA[Rapid rise in incidence of Irish paediatric inflammatory bowel disease]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300651v1?rss=1</link>
<description><![CDATA[<sec><st>Aims</st><p>To describe the change in incidence of paediatric inflammatory bowel disease (IBD) observed at the National Centre for Paediatric Gastroenterology, Hepatology and Nutrition, and to determine whether the presenting disease phenotype and disease outcomes have changed during the past decade.</p></sec><sec><st>Methods</st><p>The annual incidence of IBD in Irish children aged &lt;16 years was calculated for the years 2000&ndash;2010. Two subsets of patients, group A (diagnosed between 1 January 2000 and 31 December 2001), and group B (diagnosed between 1 January and 31 December 2008) were phenotyped according to the Paris Classification. Phenotype at diagnosis and 2-year follow-up were then compared.</p></sec><sec><st>Results</st><p>406 new cases of IBD were identified. The incidence was 2.5/100 000/year in 2001, 7.3 in 2008 and 5.6 in 2010, representing a significant increase in the number of new cases of Crohn's disease (CD) and ulcerative colitis (UC). There were 238 cases of CD; 129 of UC; and 39 of IBD unclassified. Comparing groups A and B, no differences were found in disease location at diagnosis or, for CD, in its behaviour.</p></sec><sec><st>Conclusions</st><p>There has been a substantial and sustained increase in the incidence of childhood UC and CD in Ireland over a relatively short period of time. However, disease phenotype at diagnosis has not changed. At 2 years follow-up, CD appears to progress less frequently than in some neighbouring countries. These variations remain unexplained. Prospective longitudinal studies will help to elucidate further the epidemiology of childhood IBD.</p></sec>]]></description>
<dc:creator><![CDATA[Hope, B., Shahdadpuri, R., Dunne, C., Broderick, A. M., Grant, T., Hamzawi, M., O'Driscoll, K., Quinn, S., Hussey, S., Bourke, B.]]></dc:creator>
<dc:date>2012-05-01T02:03:50-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300651</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300651</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Crohn's disease, Ulcerative colitis, Epidemiologic studies, Childhood nutrition, Childhood nutrition (paediatrics)]]></dc:subject>
<dc:title><![CDATA[Rapid rise in incidence of Irish paediatric inflammatory bowel disease]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301093v1?rss=1">
<title><![CDATA[Double checking the administration of medicines: what is the evidence? A systematic review]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301093v1?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To evaluate the evidence for double checking the administration of medicines.</p></sec><sec><st>Design</st><p>A systematic search of six electronic databases&mdash;Embase, Medline, British Nursing Index and Archive, CINAHL, National electronic library for Medicines (NeLM) and PsycINFO&mdash;for all articles describing double checking of medication and dose calculation, for either dispensing or administration in both adults and children up to and including October 2010.</p></sec><sec><st>Results</st><p>Sixteen articles met the inclusion criteria. There were only three quantitative studies. Only one of these was a randomised controlled clinical trial in a clinical setting. This study showed a statistically significant reduction in the medication error rate from 2.98 (95% CI 2.45 to 3.51) to 2.12 (95% CI 1.69 to 2.55) per 1000 medications administered with double checking. One study reported a reduction in dispensing errors, by a hospital pharmacy, from 9.8 to 6 per year following the introduction of double checking. The majority of the studies were qualitative and involved interviews, focus groups and questionnaires.</p></sec><sec><st>Conclusion</st><p>There is insufficient evidence to either support or refute the practice of double checking the administration of medicines. Clinical trials are needed to establish whether double checking medicines are effective in reducing medication errors.</p></sec>]]></description>
<dc:creator><![CDATA[Alsulami, Z., Conroy, S., Choonara, I.]]></dc:creator>
<dc:date>2012-05-01T02:03:49-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301093</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301093</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unwanted effects / adverse reactions]]></dc:subject>
<dc:title><![CDATA[Double checking the administration of medicines: what is the evidence? A systematic review]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301326v1?rss=1">
<title><![CDATA[Dual energy x-ray absorptiometry and quantitative ultrasound are not interchangeable in diagnosing abnormal bones]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301326v1?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To evaluate whether dual energy x-ray absorptiometry (DXA) and quantitative ultrasound (QUS) classify the same children as &lsquo;abnormal&rsquo; (SD (z) score (SDS) &le;&ndash;2).</p></sec><sec><st>Methods</st><p>Speed of sound (SOS) was measured at the radius and tibia using QUS and lumbar spine bone mineral density (BMD) using DXA in 621 subjects aged 5&ndash;20 years; healthy 412, cystic fibrosis 117 and obese 92.</p></sec><sec><st>Results</st><p>BMD SDS positively (p&lt;0.001) and tibia SOS SDS negatively correlated with size (p&lt;0.05). Disagreement between DXA and QUS for &lsquo;abnormal&rsquo; scans occurred in 6&ndash;31%. Those with abnormal BMD and normal SOS SDS had lower mean BMI SDS than those with normal BMD and abnormal SOS SDS. SOS measurements were unobtainable in some children, especially in the obese group.</p></sec><sec><st>Conclusions</st><p>DXA and QUS identify different individuals as &lsquo;abnormal&rsquo;. Agreement between BMD and tibia SOS is lower in obese subjects. Without a gold-standard, it is difficult to determine which technique is more &lsquo;correct&rsquo;.</p></sec>]]></description>
<dc:creator><![CDATA[Williams, J. E., Wilson, C. M., Biassoni, L., Suri, R., Fewtrell, M. S.]]></dc:creator>
<dc:date>2012-05-01T02:03:49-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301326</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301326</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Pancreas and biliary tract, Obesity (nutrition), Child health, Radiology, Cystic fibrosis, Clinical diagnostic tests, Radiology (diagnostics), Health education, Obesity (public health), Health promotion]]></dc:subject>
<dc:title><![CDATA[Dual energy x-ray absorptiometry and quantitative ultrasound are not interchangeable in diagnosing abnormal bones]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Short research report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301501v1?rss=1">
<title><![CDATA[The impact of early identification of permanent childhood hearing impairment on speech and language outcomes]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301501v1?rss=1</link>
<description><![CDATA[<p>It is well established that permanent childhood hearing impairment (PCHI) has a detrimental impact on speech and language development. The past two decades have seen the gradual introduction of universal newborn hearing screening (UNHS) programmes coupled with early intervention programmes. We review studies that have capitalised on the advent of newborn hearing screening to assess the impact of early identification of PCHI on language outcomes in deaf children. The research supports the conclusion that, in children with PCHI, newborn hearing screening and early identification lead to beneficial effects on language development, with the most consistent evidence provided for links between early identification of PCHI and positive language outcomes. Future research needs to encompass a wider range of outcomes and to assess the impact of UNHS in adolescents and young adults.</p>]]></description>
<dc:creator><![CDATA[Pimperton, H., Kennedy, C. R.]]></dc:creator>
<dc:date>2012-05-01T02:03:48-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301501</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301501</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Disability, Ear, nose and throat/otolaryngology, Screening (epidemiology), Screening (public health)]]></dc:subject>
<dc:title><![CDATA[The impact of early identification of permanent childhood hearing impairment on speech and language outcomes]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Global child health</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301794v1?rss=1">
<title><![CDATA[Teenage abortion and consent]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301794v1?rss=1</link>
<description><![CDATA[<p>Despite articles on consent,<cross-ref type="bib" refid="R1">1</cross-ref> parental responsibility,<cross-ref type="bib" refid="R2">2</cross-ref> safeguarding in adolescence<cross-ref type="bib" refid="R3">3</cross-ref> and teenage pregnancy,<cross-ref type="bib" refid="R4">4</cross-ref> central problems of consent in relation to underage sexual activity remain concealed, particularly when a pregnant girl under 16 years wishes to have a termination, without her parents knowing. The medical, legal, social and psychological issues may make a paediatrician the appropriate professional to assess competence and safety.</p><p>The interview must allow the girl to be alone with the paediatrician. The time is arranged by mobile phone, often at the end of the school day, and in a different building from the maternity/gynaecology unit. An hour will be needed. Her confidentiality must be respected unless one receives information which puts her in danger. Hospital records should have been consulted. Telephone calls are the best way of communication with the referring general practitioner or social services, with the agreement that the call...]]></description>
<dc:creator><![CDATA[Wilson, R. G.]]></dc:creator>
<dc:date>2012-04-25T02:03:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301794</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301794</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Teenage abortion and consent]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301719v1?rss=1">
<title><![CDATA[Benign mesenchymoma presenting as a paraspinal mass]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301719v1?rss=1</link>
<description><![CDATA[<p>A 4-year-old girl was brought to clinical attention with a complaint of swelling in lower back, which gradually enlarged. Physical examination revealed a firm globular mass in the right paraspinal region at L1 to L4 level (<cross-ref type="fig" refid="F1">figure 1A</cross-ref>). Digital radiograph showed a circumscribed mass lesion with central calcification in the right paravertebral region at the level of L3 and L4 vertebrae (<cross-ref type="fig" refid="F1">figure 1B</cross-ref>). Contrast-enhanced CT scan revealed a hypodense soft tissue tumour with central calcification and heterogeneous contrast enhancement (<cross-ref type="fig" refid="F1">figure 1C</cross-ref>). A radiological impression of the benign soft tissue tumour was rendered. The tumour was excised and was comprised of a mass measuring 7.5<FONT FACE="arial,helvetica">x</FONT>5<FONT FACE="arial,helvetica">x</FONT>2 cm in size with attached skeletal muscle and fibro-fatty tissue. The cut-section showed a circumscribed grey white to grey brown lesion measuring 6<FONT FACE="arial,helvetica">x</FONT>2 cm (<cross-ref type="fig" refid="F1">figure 1D</cross-ref>). There was a central bony area. Multiple sections from the lesion showed...]]></description>
<dc:creator><![CDATA[Jain, S., Agarwal, A., Bansal, K., Gupta, R.]]></dc:creator>
<dc:date>2012-04-25T02:03:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301719</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301719</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oncology, Journalology, Pathology, Radiology, Clinical diagnostic tests, Radiology (diagnostics), Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[Benign mesenchymoma presenting as a paraspinal mass]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301989v1?rss=1">
<title><![CDATA[Two-week urgent referrals for suspected childhood cancer: experience within a large tertiary centre]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301989v1?rss=1</link>
<description><![CDATA[<p>In a recently published article on the role of the 2-week urgent referral system for suspected childhood cancer,<cross-ref type="bib" refid="R1">1</cross-ref> Mant and Nanduri consider whether their findings, among the 35 patients referred to this system, might be representative of the wider population. We recently analysed our suspected cancer referral data for January 2009&ndash;December 2011. During this 3-year period, we received 312 such referrals. Our hospital is the main secondary care centre for paediatrics in Bristol and the surrounding area (resident population aged 16 years and under, 202 300), and also the tertiary centre for paediatric oncology in the southwest. The vast majority of 2-week urgent referrals are seen in the consultant-delivered general paediatric rapid access clinic, with a small number of specific patients being redirected (for example, suspected melanoma to dermatology, breast lumps in teenage girls to the breast service).</p><p>Of those referred, using the suspected cancer system, the numbers diagnosed...]]></description>
<dc:creator><![CDATA[Bragonier, R., Kenyon, C.]]></dc:creator>
<dc:date>2012-04-25T02:03:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301989</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301989</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Two-week urgent referrals for suspected childhood cancer: experience within a large tertiary centre]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300806v1?rss=1">
<title><![CDATA[Hyperthyrotropinaemia in untreated subjects with down's syndrome aged 6 months to 64 years: a comparative analysis]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300806v1?rss=1</link>
<description><![CDATA[<sec><st>Objectives</st><p>To determine whether an altered hypothalamic-pituitary-thyroid axis is inherent to Down's syndrome or if a high level of thyroid-stimulating hormone (TSH) is a feature in a subset of patients with Down's syndrome.</p></sec><sec><st>Design</st><p>Comparative analysis.</p></sec><sec><st>Setting</st><p>Major health maintenance organisation (3.8 million insured).</p></sec><sec><st>Patients</st><p>A data warehouse search identified all subjects with Down's syndrome who attended Clalit Health Services in 2006 and were tested for TSH and free thyroxine (T4) level on the day of diagnosis (intention-to-treat population). The study group consisted of patients who were not diagnosed with thyroid disease or did not receive thyroid-modulating medication (n=428). Their findings were compared with a control group of healthy age- and sex-matched subjects who were randomly selected from the general population.</p></sec><sec><st>Main outcome measures</st><p>Distribution of free T4, TSH and total T3 levels.</p></sec><sec><st>Results</st><p>The distribution plot for TSH showed a significant shift of the curve to higher values in the study group compared with the controls (p&le;0.0001). This finding held true on further analysis of the whole intention-to-treat population (p&lt;0.006). The free T4 distribution curve also shifted significantly to higher levels in patients with Down's syndrome (p&le;0.0001).</p></sec><sec><st>Conclusions</st><p>Down's syndrome is associated with higher TSH levels. The results suggest that hyperthyrotropinaemia is an innate attribute of chromosome 21 trisomy. Therefore, T4 treatment should not be contemplated in Down's Syndrome unless the TSH is &gt;95th centile in the presence of normal-range free T4 levels.</p></sec>]]></description>
<dc:creator><![CDATA[Meyerovitch, J., Antebi, F., Greenberg-Dotan, S., Bar-Tal, O., Hochberg, Z.]]></dc:creator>
<dc:date>2012-04-25T02:03:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300806</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300806</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Drugs: CNS (not psychiatric), Thyroid disease]]></dc:subject>
<dc:title><![CDATA[Hyperthyrotropinaemia in untreated subjects with down's syndrome aged 6 months to 64 years: a comparative analysis]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300829v1?rss=1">
<title><![CDATA[Epidemiology of diagnosed childhood cancer in western kenya]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300829v1?rss=1</link>
<description><![CDATA[<sec><st>Setting</st><p>Basic epidemiological information on childhood cancer in Western Kenya is lacking. This deficit obstructs efforts to improve the care and survival rates of children in this part of the world.</p></sec><sec><st>Objective</st><p>Our study provides an overview of childhood cancer patients presenting for treatment in Western Kenya.</p></sec><sec><st>Design</st><p>A retrospective analysis of childhood cancer patients presenting for treatment in Western Kenya was carried out using information from three separate databases at the Moi Teaching and Referral Hospital in Eldoret. All patients aged 0&ndash;19 years first presenting between January 2006 and January 2010 with a newly diagnosed malignancy were included.</p></sec><sec><st>Results</st><p>A total of 436 children with cancer were registered during the period. There were 256 (59%) boys and 180 (41%) girls with a male/female ratio of 1.4:1. The group aged 6&ndash;10 years contained most children (29%). Median age at admission was 8 years. Non-Hodgkin's lymphoma was the most common type of cancer (34%), followed by acute lymphoblastic leukaemia (15%), Hodgkin's lymphoma (8%), nephroblastoma (8%), rhabdomyosarcoma (7%), retinoblastoma (5%) and Kaposi's sarcoma (5%). Only four (1%) children with brain tumours were documented. Ewing's sarcoma was not diagnosed.</p></sec><sec><st>Conclusions</st><p>Our study provides an overview of childhood cancer patients presenting for treatment in Western Kenya. The distribution of malignancies is similar to findings from other equatorial African countries but differs markedly from studies in high-income countries. The new comprehensive cancer registration system will be continued and extended to serve as the basis for an evidence-based oncology program. Eventually this may lead to improved clinical outcomes.</p></sec>]]></description>
<dc:creator><![CDATA[Mostert, S., Njuguna, F., Kemps, L., Strother, M., Aluoch, L., Buziba, G., Kaspers, G.]]></dc:creator>
<dc:date>2012-04-25T02:03:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300829</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300829</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oncology, Urology, Immunology (including allergy), Neurooncology, Renal medicine, Rheumatology]]></dc:subject>
<dc:title><![CDATA[Epidemiology of diagnosed childhood cancer in western kenya]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300272v1?rss=1">
<title><![CDATA[Fatal laryngeal diphtheria in a UK child]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300272v1?rss=1</link>
<description><![CDATA[<p>Over the last century, the infectious causes of acute upper airway obstruction have changed dramatically. Toxigenic <I>Corynebacterium diphtheriae</I> has become rare in the UK due to national immunisation programmes. Since 1986, eight sporadic cases of <I>C diphtheriae</I> were reported, all of whom had recently returned from endemic areas. We describe a case of fatal laryngeal diphtheria in an unimmunised child. Although appropriate antimicrobial cover was provided, antitoxin was not administered due to a low index of suspicion. This case represents the first UK death from <I>C diphtheriae</I> in 14 years and where travel to an endemic country or contact with a known case of diphtheria was not identified. We highlight the need to maintain a high index of suspicion in children for whom completion of the immunisation schedule is not confirmed regardless of travel history. Prompt recognition and timely administration of antitoxin may be life-saving.</p>]]></description>
<dc:creator><![CDATA[Ganeshalingham, A., Murdoch, I., Davies, B., Menson, E.]]></dc:creator>
<dc:date>2012-04-25T02:03:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300272</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300272</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Vaccination / immunisation]]></dc:subject>
<dc:title><![CDATA[Fatal laryngeal diphtheria in a UK child]]></dc:title>
<prism:publicationDate>2012-04-25</prism:publicationDate>
<prism:section>Case report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301496v1?rss=1">
<title><![CDATA[Postexposure chickenpox prophylaxis in children with leukaemia: a reply to the recent PEPtalk study and report of a service evaluation in a tertiary paediatric haematology centre in the UK]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301496v1?rss=1</link>
<description><![CDATA[<p>A recent paper by Bate <I>et al</I> (&lsquo;PEPtalk: postexposure prophylaxis against varicella in children with cancer&rsquo;)<cross-ref type="bib" refid="R1">1</cross-ref> reports national data regarding practice in postexposure prophylaxis (PEP) of chickenpox in immunocompromised children. We provide additional depth of detail regarding practice in a large tertiary paediatric haematology unit in England by presenting a service evaluation of postexposure chickenpox prophylaxis in children with leukaemia. We also highlight the probability of underestimated cases of PEP and clinical chickenpox in the paper by Bate <I>et al</I>.</p><p>While chickenpox in healthy children is normally mild and self-limiting, in immunocompromised children it can cause severe morbidity and even mortality. For this reason, optimising PEP to prevent clinical disease in these patients is essential. Our paediatric haemato-oncology unit was one of 12 included in the observational study of Bate <I>et al</I>. However, while the number of centres studied in PEPtalk meant a necessary reliance on survey data, in...]]></description>
<dc:creator><![CDATA[Samuelson, C. V., Rambani, R., Vora, A. J.]]></dc:creator>
<dc:date>2012-04-20T02:01:12-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301496</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301496</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Postexposure chickenpox prophylaxis in children with leukaemia: a reply to the recent PEPtalk study and report of a service evaluation in a tertiary paediatric haematology centre in the UK]]></dc:title>
<prism:publicationDate>2012-04-20</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300853v1?rss=1">
<title><![CDATA[Poor sensitivity of musculoskeletal history in children]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300853v1?rss=1</link>
<description><![CDATA[<sec><st>Objectives</st><p>To demonstrate the sensitivity of musculoskeletal (MSK) history taking.</p></sec><sec><st>Design</st><p>Prospective study: consecutive children attending outpatient clinics.</p></sec><sec><st>Setting and patients</st><p>Paediatric rheumatology clinic (n=45; girls n=28; median age 12 years, range 3&ndash;18), acute general paediatric assessment unit (n=50; girls n=21; median age 8 years, range 3&ndash;16).</p></sec><sec><st>Intervention</st><p>Pro forma recording abnormal joint involvement from history taking and then following MSK examination completed by clinicians.</p></sec><sec><st>Main outcome measures</st><p>Sensitivity of MSK history taking compared with clinical examination.</p></sec><sec><st>Results</st><p>Paediatric rheumatology clinic: 135 abnormal joints identified in 34 children; 53/135 (39%) by history alone, 82/135 (61%) detected on examination resulting in MSK history sensitivity 53%, specificity 98%. Acute paediatric unit: 29 abnormal joints identified in 17 children; 18/29 identified on history (sensitivity 62%).</p></sec><sec><st>Conclusions</st><p>MSK history taking failed to identify a large number of abnormal joints which were detected on physical examination, emphasising the need for all joints to be examined as part of a screening examination as a minimum.</p></sec>]]></description>
<dc:creator><![CDATA[Goff, I., Rowan, A., Bateman, B. J., Foster, H. E.]]></dc:creator>
<dc:date>2012-04-13T02:01:52-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300853</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300853</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Child health, Rheumatology, Screening (epidemiology), Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Poor sensitivity of musculoskeletal history in children]]></dc:title>
<prism:publicationDate>2012-04-13</prism:publicationDate>
<prism:section>Short research report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300653v1?rss=1">
<title><![CDATA[Percutaneous gastrojejunostomy in children: efficacy and safety]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300653v1?rss=1</link>
<description><![CDATA[<p>Transgastric jejunal intubation via gastrostomy (GJ) can be indicated when enteral nutrition via gastrostomy is not possible. Between 2001 and 2008, the authors prospectively assessed the outcomes in 29 patients (median age, 10 months) after GJ. Indications for jejunal feeding were severe gastro-oesophageal reflux (n=27) and intestinal dysmotility (n=2). The GJ was successfully placed in 27/29 patients. Complications were: 31 tube dislodgements, 16 obstructions, 7 leakages around the tube, 6 internal balloon ruptures and 1 intussusception. The median lifetime of the tube was 3 months. 9/27 patients died during the study period, 11 patients required surgery, 2 required parenteral nutrition, gastric feeding became tolerated in 3 and the gastrojejunal feeding tube was kept in place in the remaining 2. A transgastric jejunal feeding tube may constitute a transitory alternative to antireflux surgery or prolonged parenteral nutrition. However, the high frequency of complications and tube replacement limits its use.</p>]]></description>
<dc:creator><![CDATA[Michaud, L., Coopman, S., Guimber, D., Sfeir, R., Turck, D., Gottrand, F.]]></dc:creator>
<dc:date>2012-04-13T02:01:52-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300653</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300653</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oesophagus, Childhood nutrition, Childhood nutrition (paediatrics)]]></dc:subject>
<dc:title><![CDATA[Percutaneous gastrojejunostomy in children: efficacy and safety]]></dc:title>
<prism:publicationDate>2012-04-13</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301476v1?rss=1">
<title><![CDATA[Practical issues in relation to clinical trials in children in low-income countries: experience from the front line]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301476v1?rss=1</link>
<description><![CDATA[<p>Clinical trials in children in resource-poor environments are essential for local health policy and practice to be relevant and evidence based. Research must be ethical, appropriate, relevant and of good quality. It should, where possible, benefit the subjects studied,the clinical, scientific and support staff involved, and the service and academic institutions of the host country. The challenge for researchers and their sponsors is to maximise such benefits while avoiding the many possible pitfalls.</p>]]></description>
<dc:creator><![CDATA[Molyneux, E., Mathanga, D., Witte, D., Molyneux, M.]]></dc:creator>
<dc:date>2012-04-13T02:01:52-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301476</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301476</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Practical issues in relation to clinical trials in children in low-income countries: experience from the front line]]></dc:title>
<prism:publicationDate>2012-04-13</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301864v1?rss=1">
<title><![CDATA[Chest mass in a 13-year-old boy]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301864v1?rss=1</link>
<description><![CDATA[<p>A previously healthy 13-year-old boy was referred to the pulmonary clinic for evaluation for persistent cough and opacity on chest x-ray after treatment with three different antibiotics. The physical examination was unremarkable and chest x-ray showed opacity (<cross-ref type="fig" refid="F1">figure 1A</cross-ref>) with homogeneous density and sharp margins. Lateral view (<cross-ref type="fig" refid="F1">figure 1B</cross-ref>) suggested that it was anterior to the heart. Chest CT (<cross-ref type="fig" refid="F1">figure 1C</cross-ref>) confirmed anterior position with well-defined margins and no involvement of lung parenchyma. Coronal reverse image (<cross-ref type="fig" refid="F1">figure 1D</cross-ref>) showed a defect in the diaphragm from which abdominal omental fat was seen herniating into the thoracic cavity, suggestive of Morgagni hernia. The patient underwent surgical repair of Morgagni hernia without any complications.</p><p>Morgagni hernias are the least common of all diaphragmatic defects<cross-ref type="bib" refid="R1">1</cross-ref> and are usually asymptomatic, unless associated with other malformations (cardiac defects, omphalocele, trisomy 21). They are more common on the...]]></description>
<dc:creator><![CDATA[Guglani, L., Broyles, J., Gaines, B. A., Finder, J. D.]]></dc:creator>
<dc:date>2012-04-03T02:02:11-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301864</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301864</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oncology, Journalology, Oesophagus, Small intestine, Immunology (including allergy), Drugs: infectious diseases, Drugs: CNS (not psychiatric), Child health, Radiology, Rheumatology, Clinical diagnostic tests, Radiology (diagnostics), Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[Chest mass in a 13-year-old boy]]></dc:title>
<prism:publicationDate>2012-04-03</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300305v1?rss=1">
<title><![CDATA[The epidemiology of hypernatraemia in hospitalised children in Lothian: a 10-year study showing differences between dehydration, osmoregulatory dysfunction and salt poisoning]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300305v1?rss=1</link>
<description><![CDATA[<sec><st>Introduction</st><p>The relative frequencies of the causes of hypernatraemia in children after the neonatal period are unknown. Salt poisoning and osmoregulatory dysfunction are extremely rare and potentially fatal. In this retrospective 10-year study, the incidence, causes and differential biochemistry of hypernatraemia in children is examined.</p></sec><sec><st>Methods</st><p>Children with hypernatraemia (sodium &ge;150 mmol/litre) aged &gt;2 weeks to 17 years were identified from laboratory data of two paediatric departments serving the Lothian region of Scotland. A review of patient notes established time of onset and cause. Denominator data were available from the Scottish Health Service.</p></sec><sec><st>Results</st><p>On admission to hospital, 1 in 2288 children (1:1535 admitted as an emergency) had hypernatraemia. This is 1 in 30 563 Lothian children &lt;17 years. Overall 0.04% hospital stays had an episode of hypernatraemia. In 45 children admitted with 64 separate episodes (11 from a case of salt poisoning), the commonest cause was dehydration secondary to either gastroenteritis or systemic infection; 31% had an underlying chronic neurological disorder. A total of 177 further cases developed hypernatraemia after admission. The commonest causes were dehydration secondary to severe systemic infection and postoperative cardiac surgery. Urine sodium:creatinine ratio and fractional excretion of sodium were both much higher in the salt poisoning case than in a child with osmoregulatory dysfunction or children with simple dehydration.</p></sec><sec><st>Conclusions</st><p>Hypernatraemia after 2 weeks of age is uncommon, and on admission is usually associated with dehydration. Salt poisoning and osmoregulatory dysfunction are rare but should be considered in cases of repeated hypernatraemia without obvious cause. Routine measurement of urea, creatinine and electrolytes on paired urine and plasma on admission will differentiate these rare causes.</p></sec>]]></description>
<dc:creator><![CDATA[Forman, S., Crofton, P., Huang, H., Marshall, T., Fares, K., McIntosh, N.]]></dc:creator>
<dc:date>2012-04-03T02:02:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300305</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300305</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Infection (gastroenterology), Foodborne infections, Child health, Poisoning, Metabolic disorders, Occupational and environmental medicine]]></dc:subject>
<dc:title><![CDATA[The epidemiology of hypernatraemia in hospitalised children in Lothian: a 10-year study showing differences between dehydration, osmoregulatory dysfunction and salt poisoning]]></dc:title>
<prism:publicationDate>2012-04-03</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301561v1?rss=1">
<title><![CDATA[Measles in a mother and her newborn baby]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301561v1?rss=1</link>
<description><![CDATA[<p>A previously healthy 35-year-old Swiss woman at 38<sup>5/7</sup> weeks of gestation with mild fever, conjunctivitis, coryza and cough for 4 days delivered a baby boy weighing 3.15 kg without neonatal alarm indicators. Some hours later she developed a maculopapular rash starting around the hairline, neck and face and subsequently spreading cephalocaudally and centrifugally (<cross-ref type="fig" refid="F1">Figure 1A,C</cross-ref>). The clinical diagnosis of measles, made based on the history, the distinctive rash and the presence of Koplik's spots, was confirmed by the presence of measles-specific immunoglobulin M in blood and detection of measles virus by reverse transcription-PCR testing in saliva.<cross-ref type="bib" refid="R1">1</cross-ref></p><p>The newborn child was administered prophylactically polyclonal intravenous immunoglobulins. On the 4th day of life, a maculopapular rash (<cross-ref type="fig" refid="F1">Figure 1B,D</cross-ref>) and Koplik's spots were noted. The course of measles, whose diagnosis was further supported by detection of the virus in saliva, was uneventful without fever, conjunctivitis, tachypnea, nasal flaring,...]]></description>
<dc:creator><![CDATA[Peruzzo, M., Giannini, O., Bianchetti, M. G.]]></dc:creator>
<dc:date>2012-04-03T02:02:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301561</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301561</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Journalology, Eye Diseases, Immunology (including allergy), Drugs: infectious diseases, Vaccination / immunisation, Ophthalmology, Complementary medicine, Clinical diagnostic tests, Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[Measles in a mother and her newborn baby]]></dc:title>
<prism:publicationDate>2012-04-03</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301150v1?rss=1">
<title><![CDATA[Antibiotic use in children and the use of medicines by parents]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301150v1?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>Antibiotic drugs are frequently used for viral infections in children. It is probable that health beliefs and parental concern have great influence on the use of drugs in children. This study, performed in The Netherlands, investigates whether the use of antibiotics in children is associated with the use of medicines by parents.</p></sec><sec><st>Patients and methods</st><p>In this observational cohort study, the authors selected 6731 children from the prescription database IADB.nl who did not receive antibiotics until their fifth birthday and 1479 children who received at least one antibiotic prescription every year. The authors then selected parents for each group of children (5790 mothers and 4250 fathers for the children who did not receive antibiotics and 1234 mothers and 1032 fathers for the children who regularly received antibiotics). The authors compared the use of antibiotics and other medicines between the two groups of parents.</p></sec><sec><st>Results</st><p>Parents of children who received antibiotics recurrently were found to use more antibiotics themselves compared with parents of children who did not receive antibiotics. Moreover, this group also showed a higher percentage of chronic medication use: (11.3 vs 6.2% (mothers) and 13.1% vs 9.5% (fathers)). Mothers more often use antacids, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, anxiolytics, hypnotics, antidepressants, drugs for treatment of asthma and antihistamines. Fathers use more antacids, cardiovascular drugs, NSAIDs and asthma drugs.</p></sec><sec><st>Conclusions</st><p>The parents of children who receive antibiotic drugs regularly use more medicines compared with the parents of children who use no antibiotic drugs. Parents' medicine use may influence that of children and is a factor physicians and pharmacists should take into account.</p></sec>]]></description>
<dc:creator><![CDATA[de Jong, J., Bos, J. H. J., de Vries, T. W., de Jong-van den Berg, L. T. W.]]></dc:creator>
<dc:date>2012-03-29T02:01:22-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301150</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301150</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Immunology (including allergy), Drugs: infectious diseases, Drugs: cardiovascular system, Pain (neurology), Child and adolescent psychiatry (paedatrics), Child health, Pain (palliative care), Asthma, Drugs: respiratory system]]></dc:subject>
<dc:title><![CDATA[Antibiotic use in children and the use of medicines by parents]]></dc:title>
<prism:publicationDate>2012-03-29</prism:publicationDate>
<prism:section>Drug therapy</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301810v1?rss=1">
<title><![CDATA[Severe hyperlipidaemia complicating diabetic ketoacidosis]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301810v1?rss=1</link>
<description><![CDATA[<p>An 8-year-old girl presented with diabetic ketoacidosis (DKA) following 6 months of malaise, 1 month of perineal candidiasis and 1 week of polyuria and polydipsia. She had Kussmaul respirations, but was fully conscious. Blood glucose was 34.9 mmol/l, pH 7.0 and bicarbonate 6.8 mmol/l.</p><p>Her venous blood appeared grossly lipaemic (<cross-ref type="fig" refid="F1">figure 1</cross-ref>). Triglyceride levels on admission were 122.63 mmol/l (ref &lt;2.3 mmol/l). HbA1c on admission was 19.5%.</p><p>The girl was treated according to the standard UK protocol for DKA (BSPED&mdash;<A HREF="http://www.bsped.org.uk">http://www.bsped.org.uk</A>); however, accurate monitoring of electrolytes was not possible in the first 48 h of treatment due to the hyperlipidaemia, so fluid management was based on clinical evaluation, blood gases and strict adherence to the protocol. After 48 h, blood gases had normalised and subcutaneous insulin was commenced. Venous blood remained grossly lipaemic until day 3. The girl was discharged home on day 5. Triglyceride levels were monitored and...]]></description>
<dc:creator><![CDATA[Williamson, S., Alexander, V., Greene, S. A.]]></dc:creator>
<dc:date>2012-03-23T02:03:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301810</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301810</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Urology, Journalology, Child health, Competing interests (ethics), Diabetes, Metabolic disorders]]></dc:subject>
<dc:title><![CDATA[Severe hyperlipidaemia complicating diabetic ketoacidosis]]></dc:title>
<prism:publicationDate>2012-03-23</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301696v1?rss=1">
<title><![CDATA[The danger of biopsy in fibrodysplasia ossificans progressiva]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301696v1?rss=1</link>
<description><![CDATA[<p>A 2-year-old girl presented with episodic soft tissue swellings for over a year and polyarticular stiffness for half a year. The swellings were painful and mainly involved her head, neck and back region (<cross-ref type="fig" refid="F1">figure 1</cross-ref>). Her neck and shoulders had very limited mobility. Malformations of the great toes were discovered during the physical examination (<cross-ref type="fig" refid="F2">figure 2</cross-ref>). The biopsy of the cephalic swelling done in the local hospital suggested aggressive juvenile fibromatosis, but the swelling enlarged rapidly immediately after the biopsy (<cross-ref type="fig" refid="F3">figure 3</cross-ref>). Fibrodysplasia ossificans progressiva (FOP) was suspected, and the diagnosis was confirmed by the test for the gene of activin A receptor, type I.</p><p>FOP is a rare genetic disease with two clinical features: progressive heterotopic endochondral ossification and malformations of the great toes. Early fibroproliferative lesions of FOP are histologically indistinguishable from aggressive juvenile fibromatosis<cross-ref type="bib" refid="R1">1</cross-ref> and the diagnosis does not rely...]]></description>
<dc:creator><![CDATA[Zan, X., Wang, J., You, C.]]></dc:creator>
<dc:date>2012-03-23T02:03:18-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301696</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301696</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Surgery, Journalology, Clinical genetics, Pathology, Radiology, Rheumatology, Surgical diagnostic tests, Clinical diagnostic tests, Competing interests (ethics), Drugs: endocrine system]]></dc:subject>
<dc:title><![CDATA[The danger of biopsy in fibrodysplasia ossificans progressiva]]></dc:title>
<prism:publicationDate>2012-03-23</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301284v1?rss=1">
<title><![CDATA[Investigation and management of hypercalcaemia in children]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301284v1?rss=1</link>
<description><![CDATA[<p>Hypercalcaemia is a far less common finding in children than in adults. It may present with characteristic symptoms or may be identified as a coincidental finding in children investigated for a variety of complaints. Assessment of hypercalcaemia requires an understanding of the normal physiological regulation of plasma calcium by the combined actions of parathyroid hormone, 1,25-dihydroxyvitamin D<SUB>3</SUB> and the calcium sensing receptor. Hypercalcaemia will usually require treatment using a number of different modalities but occasionally it can be due to a benign asymptomatic condition that requires no intervention. This article presents a logical approach to the investigation and subsequent management of this condition.</p>]]></description>
<dc:creator><![CDATA[Davies, J. H., Shaw, N. J.]]></dc:creator>
<dc:date>2012-03-23T02:03:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301284</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301284</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Calcium and bone, Metabolic disorders]]></dc:subject>
<dc:title><![CDATA[Investigation and management of hypercalcaemia in children]]></dc:title>
<prism:publicationDate>2012-03-23</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301229v1?rss=1">
<title><![CDATA[Checking pregnancy status in adolescent girls before procedures under general anaesthesia]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301229v1?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>Surgery, ionising radiation and anaesthesia in the presence of an undetected pregnancy could be harmful. British guidelines state that female patients of 'childbearing age' should have their pregnancy status established before surgery. Approaching this topic with an adolescent girl can be challenging.</p></sec><sec><st>Design</st><p>The authors conducted an observational study and a survey in their institution and a national survey of Association of Paediatric Anaesthetists (APA) linkmen.</p></sec><sec><st>Setting</st><p>Local: Southampton. National: UK.</p></sec><sec><st>Results</st><p>Both surveys demonstrate widespread concerns about inconsistent and informal practices. Only 45% of respondents in the authors' institution stated they ask adolescent girls if they could be pregnant. 40% of APA linkmen were unaware of national guidelines.</p></sec><sec><st>Conclusions</st><p>This work illustrates the need for consistent national guidance. We propose that all girls who have reached menarche should be routinely offered a urine pregnancy test before any procedure under general anaesthesia.</p></sec>]]></description>
<dc:creator><![CDATA[Donaldson, J. F., Napier, S. J., Ward-Jones, M., Wheeler, R. A., Spargo, P. M.]]></dc:creator>
<dc:date>2012-03-23T02:03:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301229</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301229</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Pregnancy, Reproductive medicine, Adolescent health, Child health, Other anaesthesia]]></dc:subject>
<dc:title><![CDATA[Checking pregnancy status in adolescent girls before procedures under general anaesthesia]]></dc:title>
<prism:publicationDate>2012-03-23</prism:publicationDate>
<prism:section>Short research report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301089v1?rss=1">
<title><![CDATA[Managing bone and joint infection in children]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301089v1?rss=1</link>
<description><![CDATA[<p>There is little high quality evidence on which to base the management of bone and joint infections in children. This pragmatic practice note aims to provide a consensus framework of best current practice prior to the availability of data from large national randomised controlled trials. For straightforward infection in previously normal children, recent trends suggest that shorter length of intravenous therapy with switch to oral treatment is acceptable, although this is not the case for the management of complex infections including those with multifocal disease, significant bone destruction, resistant or unusual pathogens, sepsis or in immunosuppressed children. Flowsheets for management based on the evidence reviewed are presented.</p>]]></description>
<dc:creator><![CDATA[Faust, S. N., Clark, J., Pallett, A., Clarke, N. M. P.]]></dc:creator>
<dc:date>2012-03-22T02:01:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301089</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301089</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology)]]></dc:subject>
<dc:title><![CDATA[Managing bone and joint infection in children]]></dc:title>
<prism:publicationDate>2012-03-22</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301299v1?rss=1">
<title><![CDATA[Marketing breast milk substitutes: problems and perils throughout the world]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301299v1?rss=1</link>
<description><![CDATA[<p>On 21 May 1981 the WHO International Code of Marketing Breast Milk Substitutes (hereafter referred to as the Code) was passed by 118 votes to 1, the US casting the sole negative vote. The Code arose out of concern that the dramatic increase in mortality, malnutrition and diarrhoea in very young infants in the developing world was associated with aggressive marketing of formula. The Code prohibited any advertising of baby formula, bottles or teats and gifts to mothers or &lsquo;bribery&rsquo; of health workers. Despite successes, it has been weakened over the years by the seemingly inexhaustible resources of the global pharmaceutical industry. This article reviews the long and tortuous history of the Code through the Convention on the Rights of the Child, the HIV pandemic and the rare instances when substitute feeding is clearly essential. Currently, suboptimal breastfeeding is associated with over a million deaths each year and 10% of the global disease burden in children. All health workers need to recognise inappropriate advertising of formula, to report violations of the Code and to support efforts to promote breastfeeding: the most effective way of preventing child mortality throughout the world.</p>]]></description>
<dc:creator><![CDATA[Brady, J. P.]]></dc:creator>
<dc:date>2012-03-14T02:01:23-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301299</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301299</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Diarrhoea, Epidemiologic studies, Unlocked, Immunology (including allergy), HIV/AIDS, Childhood nutrition, Reproductive medicine, Child health, Infant health, Infant nutrition (including breastfeeding), Sexual health]]></dc:subject>
<dc:title><![CDATA[Marketing breast milk substitutes: problems and perils throughout the world]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301253v1?rss=1">
<title><![CDATA[School children's backpacks, back pain and back pathologies]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301253v1?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To investigate whether backpack weight is associated with back pain and back pathology in school children.</p></sec><sec><st>Design</st><p>Cross-sectional study.</p></sec><sec><st>Setting</st><p>Schools in Northern Galicia, Spain.</p></sec><sec><st>Patients</st><p>All children aged 12&ndash;17.</p></sec><sec><st>Interventions</st><p>Backpack weight along with body mass index, age and gender.</p></sec><sec><st>Main outcome measures</st><p>Back pain and back pathology.</p></sec><sec><st>Results</st><p>1403 school children were analysed. Of these, 61.4% had backpacks exceeding 10% of their body weight. Those carrying the heaviest backpacks had a 50% higher risk of back pain (OR 1.50 CI 95% 1.06 to 2.12) and a 42% higher risk of back pathology, although this last result was not statistically significant (OR 1.42 CI 95% 0.86 to 2.32). Girls presented a higher risk of back pain compared with boys.</p></sec><sec><st>Conclusions</st><p>Carrying backpacks increases the risk of back pain and possibly the risk of back pathology. The prevalence of school children carrying heavy backpacks is extremely high. Preventive and educational activities should be implemented in this age group.</p></sec>]]></description>
<dc:creator><![CDATA[Rodriguez-Oviedo, P., Ruano-Ravina, A., Perez-Rios, M., Garcia, F. B., Gomez-Fernandez, D., Fernandez-Alonso, A., Carreira-Nunez, I., Garcia-Pacios, P., Turiso, J.]]></dc:creator>
<dc:date>2012-03-10T09:26:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301253</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301253</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Press releases, Pain (neurology)]]></dc:subject>
<dc:title><![CDATA[School children's backpacks, back pain and back pathologies]]></dc:title>
<prism:publicationDate>2012-03-10</prism:publicationDate>
<prism:section>Short research report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2012-301731v1?rss=1">
<title><![CDATA[Cutaneous calcifications induced by heel pricks]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2012-301731v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Case report</st><p>Two-year-old twin girls presented with several small yellow/white lumps on both heels. Some of these lumps discharged white material resulting in resolution. They did not have any discomfort on walking. They were born at 26 weeks of gestation and had numerous heel pricks during their stay in the special care baby unit.</p><p>On examination, the girls had small white non-tender papules on both their heels as shown in <cross-ref type="fig" refid="F1">figure 1</cross-ref>. Serum calcium and phosphate levels were normal. A diagnosis of dystrophic calcification secondary to heel prick tests was made. At 6-month review the lesions remain unchanged. The parents were reassured that most lesions would resolve spontaneously.</p></sec><sec id="s2"><st>Discussion</st><p>Cutaneous calcified papules and nodules are a type of dystrophic calcinosis cutis. They are a recognised complication of heel prick tests performed in the neonatal period particularly in low birth weight babies.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> Lesions are typically seen...]]></description>
<dc:creator><![CDATA[Jones, E. M., Fonseka, H. S., Balasubramaniam, P.]]></dc:creator>
<dc:date>2012-03-07T02:03:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2012-301731</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2012-301731</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Journalology, Child health, Competing interests (ethics), Calcium and bone, Metabolic disorders]]></dc:subject>
<dc:title><![CDATA[Cutaneous calcifications induced by heel pricks]]></dc:title>
<prism:publicationDate>2012-03-07</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2012.301776v1?rss=1">
<title><![CDATA[Little evidence that increased choice and competition in the English National Health Service will benefit children and young people]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2012.301776v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Introduction</st><p>Government plans to increase choice and competition in the National Health Service (NHS) will be implemented from April 2012 and will affect services for all age groups. The Royal College of Paediatrics and Child Health and the NHS Confederation recently expressed concerns that this approach might impede integration and coordination of care for younger patients. They recommend that &lsquo;the Any Qualified Provider policy should only be used for child healthcare services where there are clear benefits to patients&rsquo;.<cross-ref type="bib" refid="R1">1</cross-ref></p><p>In support of the reforms, the government has presented evidence that patients are in favour of a greater choice<cross-ref type="bib" refid="R2">2</cross-ref> and that competition between providers leads to better outcomes.<cross-ref type="bib" refid="R3">3</cross-ref> This article reviews the strength of this evidence in relation to children and young people.</p></sec><sec id="s2"><st>Competition</st><p>David Cameron quotes research by Cooper <I>et al</I> arguing that more competitive healthcare markets can lead to better clinical outcomes. This study<cross-ref type="bib"...]]></description>
<dc:creator><![CDATA[Hargreaves, D. S., Viner, R. M.]]></dc:creator>
<dc:date>2012-03-07T02:03:13-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2012.301776</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2012.301776</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Little evidence that increased choice and competition in the English National Health Service will benefit children and young people]]></dc:title>
<prism:publicationDate>2012-03-07</prism:publicationDate>
<prism:section>Letter</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301236v1?rss=1">
<title><![CDATA[Lung aerosol deposition in suckling infants]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301236v1?rss=1</link>
<description><![CDATA[<sec><st>Introduction</st><p>Aerosol therapy in infants may be greatly compromised by face mask rejection due to squirming and crying. Lung aerosol deposition in crying infants may thereby be greatly reduced. Since &lsquo;suckling&rsquo; on a pacifier calms infants, they should more readily accept a face mask that incorporates a pacifier. However, since infants must breathe nasally while suckling, lung aerosol deposition may be reduced due to impaction in the nose.</p><p>The aim of the present pilot study was to compare lung aerosol deposition while suckling on a pacifier incorporated into a mask with that obtained while inhaling from a conventional mask.</p></sec><sec><st>Methods</st><p>Twelve infants &lt;12 months old and who regularly used pacifiers participated as their own controls. Lung aerosol deposition was measured scintigraphically (technetium-<sup>99m</sup>DTPA-labelled normal saline aerosol, MMAD (Mass Median Aerodynamic Diameter) 3 um and GSD (Geometric Standard Deviation) of 2) via jet nebuliser using a conventional mask versus &lsquo;suckling&rsquo; on their pacifier incorporated into a unique mask.</p></sec><sec><st>Results</st><p>Mean lung deposition (&plusmn;SD) while suckling using a mask with attached pacifier (1.6&plusmn;0.5% in the right lung) was similar to that with a conventional mask (1.7&plusmn;0.9%, p=0.81).</p></sec><sec><st>Conclusions</st><p>Lung aerosol deposition during nasal breathing while suckling on a pacifier-equipped mask is similar to that in infants breathing quietly using a conventional mask, and results comparable with previous data in infants and in nasal breathing models of an infant's upper respiratory tract. Using a pacifier during aerosol treatment in infants may be as efficient as conventional treatment without a pacifier.</p></sec>]]></description>
<dc:creator><![CDATA[Amirav, I., Luder, A., Chleechel, A., Newhouse, M. T., Gorenberg, M.]]></dc:creator>
<dc:date>2012-02-23T02:01:39-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301236</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301236</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Lung aerosol deposition in suckling infants]]></dc:title>
<prism:publicationDate>2012-02-23</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301175v1?rss=1">
<title><![CDATA[Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301175v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Introduction</st><p>Until a few years ago, a<cross-ref type="bib" refid="R1">1</cross-ref> majority of pharmaceutical drugs did not have any label for paediatric use; this situation prompted both the USA and European Union (EU) to pass specific legislation for clinical trials in children.<cross-ref type="bib" refid="R2">2</cross-ref><cross-ref type="bib" refid="R3">&ndash;</cross-ref><cross-ref type="bib" refid="R4">4</cross-ref> In Europe, extensive efforts have been made to facilitate drug development for children by setting up the Paediatric Committee at the European Medicines Agency (EMA), by implementing particular rules to enhance paediatric drug development, including orphan drugs which are often for children, and more recently by establishing the European Network of Paediatric Research at the EMA.<cross-ref type="bib" refid="R5">5</cross-ref><cross-ref type="bib" refid="R6">&ndash;</cross-ref><cross-ref type="bib" refid="R7">7</cross-ref> In the light of these efforts it is essential that other elements of the regulatory system work in the same direction and are not counterproductive. In a case study, we wish to highlight hurdles related to the ethical assessment that need to...]]></description>
<dc:creator><![CDATA[Hansson, M. G., Gattorno, M., Forsberg, J. S., Feltelius, N., Martini, A., Ruperto, N.]]></dc:creator>
<dc:date>2012-02-22T02:01:31-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301175</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301175</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases]]></dc:title>
<prism:publicationDate>2012-02-22</prism:publicationDate>
<prism:section>Editorial</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301239v1?rss=1">
<title><![CDATA[Impact of clinical pharmacist interventions in reducing paediatric prescribing errors]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301239v1?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To assess the impact of pharmacist intervention in reducing prescribing errors in paediatrics, and to analyse the clinical significance and reasons behind the errors detected.</p></sec><sec><st>Methods</st><p>Cross-sectional epidemiological study analysing the activities of the paediatric pharmacist in a maternity and children's hospital with 180 paediatric beds, between January 2007 and December 2009. The following variables were analysed: impact of the pharmacist's recommendation on patient care, reason for the intervention, clinical significance, type of negative outcome associated with the medication, acceptance rate, medication involved, intervention detection date and observations.</p></sec><sec><st>Results</st><p>A total of 1475 interventions in medical orders for 14 713 paediatric patients were recorded (40 (2.9%) extremely significant interventions and 155 (11.1%) very significant interventions). There were 1357 prescribing errors, 833 of which were dosing errors. 2.2% of the errors detected were potentially fatal (30 cases) and 14.3% (194 cases) were clinically serious. The main reason for interventions was detection of a dosage between 1.5 and 10 times higher than that recommended. The overall rate of acceptance of the pharmacist's suggestions was 94.3%. The pharmacist carried out an average of 0.019 interventions per patient day throughout the study period.</p></sec><sec><st>Conclusion</st><p>Interventions by a clinical pharmacist had a major impact on reducing prescribing errors in the study period, thus improving the quality and safety of care provided.</p></sec>]]></description>
<dc:creator><![CDATA[Fernandez-Llamazares, C. M., Calleja-Hernandez, M. A., Manrique-Rodriguez, S., Perez-Sanz, C., Duran-Garcia, E., Sanjurjo-Saez, M.]]></dc:creator>
<dc:date>2012-02-22T02:01:31-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301239</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301239</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Patients, Epidemiologic studies, Medicines regulation]]></dc:subject>
<dc:title><![CDATA[Impact of clinical pharmacist interventions in reducing paediatric prescribing errors]]></dc:title>
<prism:publicationDate>2012-02-22</prism:publicationDate>
<prism:section>Drug therapy</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300646v1?rss=1">
<title><![CDATA[Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300646v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Studies from low-income countries have suggested that diphtheria-tetanus-pertussis (DTP) vaccine provided after Bacille Calmette-Guerin (BCG) vaccination may have a negative effect on female survival. The authors examined the effect of DTP in a cohort of low birthweight (LBW) infants.</p></sec><sec><st>Methods</st><p>2320 LBW newborns were visited at 2, 6 and 12 months of age to assess nutritional and vaccination status. The authors examined survival until the 6-month visit for children who were DTP vaccinated and DTP unvaccinated at the 2-month visit.</p></sec><sec><st>Results</st><p>Two-thirds of the children had received DTP at 2 months and 50 deaths occurred between the 2-month and 6-month visits. DTP vaccinated children had a better anthropometric status for all indices than DTP unvaccinated children. Small mid-upper arm circumference (MUAC) was the strongest predictor of mortality. The death rate ratio (DRR) for DTP vaccinated versus DTP unvaccinated children differed significantly for girls (DRR 2.45; 95% CI 0.93 to 6.45) and boys (DRR 0.53; 95% CI 0.23 to 1.20) (p=0.018, homogeneity test). Adjusting for MUAC, the overall effect for DTP vaccinated children was 2.62 (95% CI 1.34 to 5.09); DRR was 5.68 (95% CI 1.83 to 17.7) for girls and 1.29 (95% CI 0.56 to 2.97) for boys (p=0.023, homogeneity test). While anthropometric indices were a strong predictor of mortality among boys, there was little or no association for girls.</p></sec><sec><st>Conclusion</st><p>Surprisingly, even though the children with the best nutritional status were vaccinated early, early DTP vaccination was associated with increased mortality for girls.</p></sec>]]></description>
<dc:creator><![CDATA[Aaby, P., Ravn, H., Roth, A., Rodrigues, A., Lisse, I. M., Diness, B. R., Lausch, K. R., Lund, N., Rasmussen, J., Biering-Sorensen, S., Whittle, H., Benn, C. S.]]></dc:creator>
<dc:date>2012-02-13T02:03:39-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300646</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300646</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Unlocked, Immunology (including allergy), Drugs: infectious diseases, Vaccination / immunisation]]></dc:subject>
<dc:title><![CDATA[Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial]]></dc:title>
<prism:publicationDate>2012-02-13</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300538v1?rss=1">
<title><![CDATA[Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300538v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Phenobarbital (PB), commonly used as the preferred treatment for neonatal seizure, is a drug that requires careful dose adjustments based on therapeutic drug monitoring. It has been reported that PB metabolism was affected by cytochrome P450 (CYP)2C19 polymorphisms in adults requiring dose adjustment.</p></sec><sec><st>Aim</st><p>This study aimed to evaluate the effects of CYP2C19 genetic polymorphisms on PB pharmacokinetics (PK) in neonates and infants with seizures.</p></sec><sec><st>Methods</st><p>CYP2C19 (wild type: CYP2C19*1/*1, heterozygous extensive metabolisers: CYP2C19*1/*2, *1/*3 and poor metabolisers: CYP2C19*2/*2, *2/*3) genetic polymorphisms in 52 neonates and infants with seizures were analysed. PK parameters were compared based on genotypes. The NONMEM program was used for population PK modelling.</p></sec><sec><st>Results</st><p>No significant difference in PB clearance (CL), volume of distribution (Vd) and concentrations were shown among the CYP2C19 genotype groups. The results of PK modelling were as follows: Vd=3590 <FONT FACE="arial,helvetica">x</FONT>(body weight (BWT)/4)<sup>0.766</sup> <FONT FACE="arial,helvetica">x</FONT>(AGE/2)<sup>0.283</sup> and CL=32.6<FONT FACE="arial,helvetica">x</FONT>(BWT/4)<sup>1.21</sup>.</p></sec><sec><st>Conclusions</st><p>PB PK parameters of neonates and infants with seizures were not significantly different among the groups with different CYP2C19 genotypes. The addition of CYP2C19 genotyping to PK models did not improve the dosing strategies in neonates and infants.</p></sec>]]></description>
<dc:creator><![CDATA[Lee, S. M., Chung, J. Y., Lee, Y. M., Park, M. S., Namgung, R., Park, K. I., Lee, C.]]></dc:creator>
<dc:date>2012-02-13T02:03:38-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300538</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300538</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Genetic screening / counselling, Epilepsy and seizures, Child health, Medicines regulation]]></dc:subject>
<dc:title><![CDATA[Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures]]></dc:title>
<prism:publicationDate>2012-02-13</prism:publicationDate>
<prism:section>Drug therapy</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301604v1?rss=1">
<title><![CDATA[Lip swelling as initial manifestation of Crohn's disease]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301604v1?rss=1</link>
<description><![CDATA[<p>A 12-year-old boy presented with a 4-year history of non-painful lower lip enlargement and perioral erythema, without gastrointestinal symptoms. Physical examination revealed vesicles, pustules, scales and crusts along all over the lower lip (<cross-ref type="fig" refid="F1">figure 1</cross-ref>). There was no evidence of lingua plicata and facial paralysis. Complete blood count (CBC) with differential, complete metabolic panel, liver function tests, folic acid, iron and vitamin B<SUB>12</SUB> levels were normal. Chest radiography and the CT showed no alterations. Biopsy showed non-caseating granulomas, diffuse and focal lymphocytes, plasma cell and histiocytic infiltrate of the lamina propria and submucosa (<cross-ref type="fig" refid="F2">figure 2</cross-ref>). Despite an absence of gastrointestinal symptoms, we suspected a cutaneous manifestation of Crohn's disease (CD) based on histology and clinical presentation. Exploratory pancolonoscopy revealed an erythematous, oedematous and ulcerated ileocaecal valve. Intestinal histology confirmed CD. In accordance with a gastroenterologist and a paediatrician, the patient was treated with high-dose systemic steroids...]]></description>
<dc:creator><![CDATA[Bruscino, N., Arunachalam, M., Galeone, M., Scarfi, F., Maio, V., Difonzo, E. M.]]></dc:creator>
<dc:date>2012-02-06T22:27:34-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301604</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301604</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Crohn's disease, Oncology, Surgery, Journalology, Immunology (including allergy), Child health, Pathology, Radiology, Dentistry and oral medicine, Dermatology, Surgical diagnostic tests, Clinical diagnostic tests, Radiology (diagnostics), Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[Lip swelling as initial manifestation of Crohn's disease]]></dc:title>
<prism:publicationDate>2012-02-06</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300854v1?rss=1">
<title><![CDATA[Bullous Henoch Schonlein purpura]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300854v1?rss=1</link>
<description><![CDATA[<p>We report a case of haemorrhagic bullous lesions in Henoch Schonlein purpura (HSP).</p><p>A 9-year-old girl presented with 2 days of right knee pain and a purpuric rash on her legs and buttocks. She was diagnosed with HSP. On the eighth day of her illness, haemorrhagic bullae began to form on her feet and ankles and her arthritis worsened (<cross-ref type="fig" refid="F1">figure 1</cross-ref>). She was treated with prednisolone 20 mg once daily from day 10 to day 18 of her illness and the bullae started healing. She later developed proteinuria but was normotensive with normal renal function.</p><p>HSP is the most common acute systemic vasculitis of childhood affecting the skin, kidneys, joints and gastrointestinal tract. Skin lesions usually consist of erythematous papules, petechiae and purpura mainly affecting the lower limbs.<cross-ref type="bib" refid="R1">1</cross-ref> Evolution of purpura to haemorrhagic bullous lesions is rare and pressure has been suggested as the main pathogenic factor. One...]]></description>
<dc:creator><![CDATA[Raymond, M., Spinks, J.]]></dc:creator>
<dc:date>2012-02-03T00:48:34-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300854</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300854</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Surgery, Urology, Journalology, Pain (neurology), Pathology, Radiology, Rheumatology, Dermatology, Surgical diagnostic tests, Clinical diagnostic tests, Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[Bullous Henoch Schonlein purpura]]></dc:title>
<prism:publicationDate>2012-02-03</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301295v1?rss=1">
<title><![CDATA[The skeletal consequences of meningococcal septicaemia]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301295v1?rss=1</link>
<description><![CDATA[<p>Meningococcal disease remains a leading cause of childhood mortality in the UK. Advances in resuscitation have resulted in survival of severely affected individuals and the long-term skeletal consequences are being increasingly recognised. The immediate management of the ischaemic limb in the context of a critically ill and haemodynamically unstable child is described and the indications for fasciotomy and amputation are considered. Long-term disability occurs as a consequence of limb malalignment and is often accompanied by significant injury to the soft tissue envelope. The function of surviving limbs can be enhanced using contemporary surgical techniques that involve realignment and lengthening. Amputees present specific difficulties due to the effect of remaining longitudinal growth on the function of the residual limb, and require surgical treatment that often continues throughout childhood. This overview considers the surgical algorithms that have evolved to treat these patients.</p>]]></description>
<dc:creator><![CDATA[Monsell, F.]]></dc:creator>
<dc:date>2012-02-03T00:48:34-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301295</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301295</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies]]></dc:subject>
<dc:title><![CDATA[The skeletal consequences of meningococcal septicaemia]]></dc:title>
<prism:publicationDate>2012-02-03</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild.2011.301180v1?rss=1">
<title><![CDATA[A disjointed effort: paediatric musculoskeletal examination]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild.2011.301180v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Musculoskeletal (MSK) symptoms are a frequent cause of emergency department attendance for children, and while most often indicative of benign or self-limiting disease, such symptoms can occasionally be the first presentation of serious illness such as leukaemia or juvenile idiopathic arthritis. MSK examination, however, is often not included as part of the routine paediatric examination. The authors aimed to evaluate how often and how thoroughly MSK examination was performed during admissions to the paediatric ward and to compare it with the examination of other symptoms in relation to the presenting complaint and eventual diagnosis.</p></sec><sec><st>Results</st><p>Medical records for 100 consecutive patients were reviewed. A poster campaign to increase awareness was then commenced along with oral and written presentations to staff regarding MSK examination. A further 100 consecutive patients were then reviewed. Only 9% of children in the initial group had routine MSK examination, rising to 32% in the second group. Where performed, MSK examination was often incomplete. Frequent errors included only examining the reported site of injury and only examining a single limb or single joint when limpness/stiffness was the presenting complaint. Non-limb joints were very rarely examined.</p></sec><sec><st>Conclusions</st><p>MSK examination is not performed routinely during paediatric admissions in contrast to the examination of other symptoms regardless of the presenting complaint. This may need to be addressed by local audit and increased undergraduate teaching.</p></sec>]]></description>
<dc:creator><![CDATA[Gill, I., Sharif, F.]]></dc:creator>
<dc:date>2012-02-03T00:48:33-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild.2011.301180</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild.2011.301180</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oncology, Immunology (including allergy), Rheumatology]]></dc:subject>
<dc:title><![CDATA[A disjointed effort: paediatric musculoskeletal examination]]></dc:title>
<prism:publicationDate>2012-02-03</prism:publicationDate>
<prism:section>Short research report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300221v1?rss=1">
<title><![CDATA[A randomised controlled trial of Hartmann's solution versus half normal saline in postoperative paediatric spinal instrumentation and craniotomy patients]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300221v1?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To compare the difference in plasma sodium at 16&ndash;18 h following major surgery in children who were prescribed either Hartmann's and 5% dextrose or 0.45% saline and 5% dextrose.</p></sec><sec><st>Design</st><p>A prospective, randomised, open label study.</p></sec><sec><st>Setting</st><p>The paediatric intensive care unit (650 admissions per annum) in a tertiary children's hospital in Brisbane, Australia.</p></sec><sec><st>Patients</st><p>The study group comprised 82 children undergoing spinal instrumentation, craniotomy for brain tumour resection, or cranial vault remodelling.</p></sec><sec><st>Interventions</st><p>Patients received either Hartmann's and 5% dextrose at full maintenance rate or 0.45% saline and 5% dextrose at two-thirds maintenance rate.</p></sec><sec><st>Main outcomes measures</st><p>Primary outcome measure: plasma sodium at 16&ndash;18 h postoperatively; secondary outcome measure: number of fluid boluses administered.</p></sec><sec><st>Results</st><p>Mean postoperative plasma sodium levels of children receiving 0.45% saline and 5% dextrose were 1.4 mmol/l (95% CI 0.4 to 2.5) lower than those receiving Hartmann's and 5% dextrose (p=0.008). In the 0.45% saline group, seven patients (18%) became hyponatraemic (Na &lt;135 mmol/l) at 16&ndash;18 h postoperatively; in the Hartmann's group no patient became hyponatraemic (p=0.01). No child in either fluid group became hypernatraemic.</p></sec><sec><st>Conclusions</st><p>The postoperative fall in plasma sodium was smaller in children who received Hartmann's and 5% dextrose compared to those who received 0.45% saline and 5% dextrose. It is suggested that Hartmann's and 5% dextrose should be administered at full maintenance rate postoperatively to children who have undergone major surgery in preference to hypotonic fluids.</p></sec>]]></description>
<dc:creator><![CDATA[Coulthard, M. G., Long, D. A., Ullman, A. J., Ware, R. S.]]></dc:creator>
<dc:date>2012-01-30T23:31:16-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300221</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300221</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oncology, Clinical trials (epidemiology), Neurooncology]]></dc:subject>
<dc:title><![CDATA[A randomised controlled trial of Hartmann's solution versus half normal saline in postoperative paediatric spinal instrumentation and craniotomy patients]]></dc:title>
<prism:publicationDate>2012-01-30</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301163v2?rss=1">
<title><![CDATA[Anaphylaxis as an adverse event following immunisation in the UK and Ireland]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301163v2?rss=1</link>
<description><![CDATA[<p><b>Anaphylaxis is a rare</b> adverse event following immunisation (AEFI) and unlikely to be detected in prelicensure vaccine trials. Previous retrospective studies have been hampered by the paucity of information available to passive reporting schemes. The aim of the present study was to estimate the incidence and clinical presentation of anaphylaxis as an AEFI using prospective active surveillance.</p><sec><st>Methods</st><p>Children under 16 in the UK and Ireland with suspected anaphylaxis as an AEFI were reported through the British Paediatric Surveillance Unit (BPSU) between September 2008 and October 2009. Paediatricians completed questionnaires on presentation, diagnosis, management and outcome.</p></sec><sec><st>Results</st><p>A total of 7 out of 15 reports met criteria for anaphylaxis following immunisation. Four of the seven children reacted more than 30 min after administration of the vaccine. Six children required treatment with intramuscular adrenaline and intravenous fluids, but all made a full recovery. Denominators were not available for all vaccines so an overall incidence was not calculated, however the estimated incidence was 12.0 per 100 000 dose for single component measles vaccine and 1.4 cases per million doses for the bivalent human papilloma virus vaccine (Cervarix, GSK).</p></sec><sec><st>Conclusions</st><p>Anaphylaxis remains a rare adverse event following immunisation. No cases were related to vaccines given as part of the &lsquo;routine&rsquo; infant and preschool immunisation programme, despite over 5.5 million vaccines being delivered in this time period. Some children had delayed onset of symptoms and this should be considered when vaccinating those at higher risk of anaphylaxis.</p></sec>]]></description>
<dc:creator><![CDATA[Erlewyn-Lajeunesse, M., Hunt, L. P., Heath, P. T., Finn, A.]]></dc:creator>
<dc:date>2012-01-23T20:58:23-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301163</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301163</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Press releases, Immunology (including allergy), Vaccination / immunisation]]></dc:subject>
<dc:title><![CDATA[Anaphylaxis as an adverse event following immunisation in the UK and Ireland]]></dc:title>
<prism:publicationDate>2012-01-23</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301458v1?rss=1">
<title><![CDATA[Mode of delivery may be the risk factor for infant infectious morbidity]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301458v1?rss=1</link>
<description><![CDATA[<p>We read with interest the article &lsquo;Hospitalisation for bronchiolitis in infants is more common after elective caesarean delivery&rsquo;.<cross-ref type="bib" refid="R1">1</cross-ref> A previous study has reported that asthma before 3 years of age is associated with planned and emergency caesareans, (with higher risk for emergency caesarean).<cross-ref type="bib" refid="R2">2</cross-ref> The suggested pathway is that gut microflora play a part in the development of the infant immune system, and children born by caesarean have atypical microflora colonisation compared to those born vaginally.<cross-ref type="bib" refid="R3">3</cross-ref> Surprisingly, Moore <I>et al</I> found that only planned caesarean had a statistically significant risk for bronchiolitis. This they attributed to differences in cytokine environment rather than the physiologic consequences of exposure to labour.<cross-ref type="bib" refid="R4">4</cross-ref> We decided to replicate the study in another population, and investigate an additional potential infectious morbidity, to test the hypothesis that any caesarean is the exposure of interest.</p><p>The state of New South Wales in...]]></description>
<dc:creator><![CDATA[Roberts, C. L., Algert, C. S., Ford, J. B., Nassar, N.]]></dc:creator>
<dc:date>2012-01-20T23:17:18-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301458</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301458</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Mode of delivery may be the risk factor for infant infectious morbidity]]></dc:title>
<prism:publicationDate>2012-01-20</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301327v1?rss=1">
<title><![CDATA[Neuroblastoma masquerading as supraventricular tachycardia: a case of super sinus tachycardia]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301327v1?rss=1</link>
<description><![CDATA[<p>A 12-week-old female infant presented to our emergency department with a 6-week history of episodic fussiness, diaphoresis, flushing and tachypnoea occurring up to four times per day and lasting 30 min per episode. Despite the frequent episodes, the infant continued to breastfeed well, with normal urine and stool output. At presentation, her heart rate was 240&ndash;260 bpm and she was initially suspected to have supraventricular tachycardia and was treated in the emergency department with vagal manoeuvres. On detailed review of the initial tracings, it was apparent that the heart rate had decreased gradually from 260 to 180 bpm over approximately 4 min in response to the vagal manoeuvres. The respiratory rate was 80 breaths per minute and blood pressure was 133/86 with a rectal temperature of 40.1&deg;C. She was alert, crying and flushed with moderate respiratory distress. Despite being cool to the extremities, she had good peripheral pulses in all...]]></description>
<dc:creator><![CDATA[Harris, K. C., Retallack, J. E., Sanatani, S.]]></dc:creator>
<dc:date>2012-01-20T23:17:18-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301327</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301327</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oncology, Journalology, Drugs: cardiovascular system, Hypertension, Childhood nutrition, Reproductive medicine, Infant nutrition (including breastfeeding), Radiology, Airway biology, Clinical diagnostic tests, Radiology (diagnostics), Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[Neuroblastoma masquerading as supraventricular tachycardia: a case of super sinus tachycardia]]></dc:title>
<prism:publicationDate>2012-01-20</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300667v1?rss=1">
<title><![CDATA[Barriers to translating diagnostic research in febrilechildren to clinical practice: a systematic review]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300667v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Although the topic of identifying febrile children at risk of serious infections has been addressed by numerous research groups, identified predictors remain diverse and implementation of results in routine practice has been limited. The aim of this paper is to discuss the problems and challenges in advancing diagnostic research in febrile children.</p></sec><sec><st>Methods</st><p>The characteristics and results of 35 studies identified from a systematic review on predictors for febrile children were evaluated.</p></sec><sec><st>Results</st><p>Current diagnostic research is mainly performed in subpopulations, defined by age and temperature limits and in paediatric emergency settings, ignoring the role of primary care. It is characterised by a dichotomous approach of outcomes and a wide variability of potential predictors. Validation of results to other settings and impact studies of prediction rules on patient outcomes are scarce. In designing diagnostic studies on children suspected of serious infections focus is needed on all clinically relevant populations within the spectrum of primary care and emergency department settings. Consensus is also needed on the definition of fever, the concept of serious infection and the set of predictors to focus on. The heterogeneity of patients in different settings and countries stress the need for continuous updating of prediction rules in routine practice. Broad validation in different clinical settings and countries and impact analysis in routine care is essential.</p></sec><sec><st>Conclusions</st><p>Scientists in the field of diagnosis of serious infection in children must agree on core design features to be incorporated in all studies in the area of diagnostic research in febrile children. This will improve evidence from future studies, and their generalisability and implementation in routine practice.</p></sec>]]></description>
<dc:creator><![CDATA[Oostenbrink, R., Thompson, M., Steyerberg, E. W., ERNIE members]]></dc:creator>
<dc:date>2012-01-04T05:01:41-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300667</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300667</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Child health]]></dc:subject>
<dc:title><![CDATA[Barriers to translating diagnostic research in febrilechildren to clinical practice: a systematic review]]></dc:title>
<prism:publicationDate>2012-01-04</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300770v1?rss=1">
<title><![CDATA[Giant hydronephrosis: uncommon presentation of a common disease]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300770v1?rss=1</link>
<description><![CDATA[<p>A 5-year-old boy presented with progressively increasing abdominal distension since birth with no associated urinary or gastrointestinal symptoms. A large, non-tender, soft, cystic intra-abdominal lump occupying almost the whole abdomen could be palpated (<cross-ref type="fig" refid="F1">figure 1</cross-ref>). Other systemic examination and all blood tests were normal.</p><p>A contrast-enhanced CT scan revealed a large complex cystic mass of size 185 <FONT FACE="arial,helvetica">x</FONT> 148 <FONT FACE="arial,helvetica">x</FONT> 300 mm occupying almost the entire left side of the abdomen and extending to the right side. The spleen, left kidney and pancreas could not be separately visualised. The stomach and gut loops were compressed to the right. The mass was predominantly fluid (<cross-ref type="fig" refid="F2">figure 2</cross-ref>).</p><p>On laparotomy, the left kidney was grossly hydronephrotic with papery thin renal parenchyma containing &gt;5 litres of haemorrhagic fluid, and there was obvious narrowing at the pelviureteric junction. Left-sided nephroureterectomy was performed. The child recovered uneventfully after surgery and is doing well on...]]></description>
<dc:creator><![CDATA[Bawa, M., Mahalik, S., Rao, K. L. N.]]></dc:creator>
<dc:date>2012-01-03T06:08:46-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300770</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300770</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Pancreas and biliary tract, Urology, Journalology, Stomach and duodenum, Immunology (including allergy), Reproductive medicine, Radiology, Renal medicine, Clinical diagnostic tests, Radiology (diagnostics), Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[Giant hydronephrosis: uncommon presentation of a common disease]]></dc:title>
<prism:publicationDate>2012-01-03</prism:publicationDate>
<prism:section>Images in paediatrics</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301308v1?rss=1">
<title><![CDATA[Plasma procalcitonin levels in children with adenovirus infection]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301308v1?rss=1</link>
<description><![CDATA[<p>The clinical picture of adenovirus infection in children is variable including fever, cough, tonsillitis, keratoconjuctivitis, acute otitis media, febrile convulsions and gastroenteritis. In contrast to other respiratory viruses, half of the children with adenovirus infection have elevated total white blood cell counts (WBC) and serum C reactive protein (CRP) levels making it difficult to differentiate this viral infection from a bacterial one.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> Plasma procalcitonin (PCT) increases within 4&ndash;6 h after initiation of bacterial infection.<cross-ref type="bib" refid="R3">3</cross-ref> The normal level of PCT in non-infected persons is under 0.05 ng/ml, and an increase to 0.5 ng/ml or greater has been proposed to distinguish between viral and bacterial infections.<cross-ref type="bib" refid="R3">3</cross-ref> <cross-ref type="bib" refid="R4">4</cross-ref> We compared PCT and CRP levels in children with adenovirus infection to evaluate whether PCT would perform better than CRP in differentiating between adenoviral and bacterial infections.</p><p>Serum CRP, plasma PCT and blood WBC were...]]></description>
<dc:creator><![CDATA[Elenius, V., Peltola, V., Ruuskanen, O., Yliharsila, M., Waris, M.]]></dc:creator>
<dc:date>2011-12-21T01:16:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301308</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301308</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Plasma procalcitonin levels in children with adenovirus infection]]></dc:title>
<prism:publicationDate>2011-12-21</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-301248v1?rss=1">
<title><![CDATA[Oesophageal atresia and tracheoesophageal fistula with right pulmonary agenesis and duplication of the azygos vein]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-301248v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Case report</st><p>A premature (35 weeks' gestation) girl developed respiratory distress immediately after birth along with frothing from the mouth. A nasogastric tube could not be passed. Breath sounds were absent on the right side of the chest and the cardiac apex beat was located on the right side. Chest x-ray revealed opacification of the right hemithorax, absence of the right lung shadow, apparent dextrocardia and a hyperaerated left lung crossing the midline (<cross-ref type="fig" refid="F1">figure 1</cross-ref>). The upper oesophagus with the feeding tube coiled in it was deviated to the right. Thoracotomy revealed absence of the right lung, two azygos veins adjacent to each other, each with three tributaries (<cross-ref type="fig" refid="F2">figure 2</cross-ref>), and a right-sided aortic arch. The patient had oesophageal atresia (OA)with distal tracheoesophageal fistula (TEF) which was repaired. The baby died on the third postoperative day from progressive respiratory failure.</p></sec><sec id="s2"><st>Discussion</st><p>The combination of pulmonary hypoplasia-aplasia (PHA)...]]></description>
<dc:creator><![CDATA[Yadav, P. S., Pant, N., Chadha, R., Choudhury, S. R.]]></dc:creator>
<dc:date>2011-11-27T21:12:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-301248</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-301248</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Surgery, Journalology, Oesophagus, Congenital heart disease, Radiology, Clinical diagnostic tests, Radiology (diagnostics), Competing interests (ethics)]]></dc:subject>
<dc:title><![CDATA[Oesophageal atresia and tracheoesophageal fistula with right pulmonary agenesis and duplication of the azygos vein]]></dc:title>
<prism:publicationDate>2011-11-27</prism:publicationDate>
<prism:section>Images in neonatal medicine</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300120v1?rss=1">
<title><![CDATA[Engaging paediatricians in planning the training of our future workforce]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300120v1?rss=1</link>
<description><![CDATA[<p>Fundamental reform to the way we train and develop our future workforce is planned. In order to successfully achieve change the engagement of those delivering care is necessary. In this study the authors used a novel participatory design to seek the opinions of medical students, foundation doctors, specialty trainees and consultants on some key statements regarding proposed improvements to postgraduate medical education. While there was overall agreement on many of the recommendations of the Temple report, some aspects were potentially divisive, with significant differences between the views of consultants and those more junior to them. This work emphasises the importance of engaging all members of the healthcare workforce, both present and future, in the reasons for, and outcomes of, healthcare reform.</p>]]></description>
<dc:creator><![CDATA[Klaber, R. E., Roland, D.]]></dc:creator>
<dc:date>2011-09-27T05:52:23-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300120</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300120</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Child health, Undergraduate, Medical humanities]]></dc:subject>
<dc:title><![CDATA[Engaging paediatricians in planning the training of our future workforce]]></dc:title>
<prism:publicationDate>2011-09-27</prism:publicationDate>
<prism:section>Short report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300603v1?rss=1">
<title><![CDATA[Children's and young people's experience of the National Health Service in England: a review of national surveys 2001-2011]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300603v1?rss=1</link>
<description><![CDATA[<sec><st>Objectives</st><p>To investigate what data are available on the National Health Service (NHS) experience of children and young people (0&ndash;24 years), and how their experience compares with that of older patients.</p></sec><sec><st>Design and data selection</st><p>Review of 38 national surveys undertaken or planned between 2001 and 2011, identified by the Department of Health (2010). Detailed analysis performed on the most recent completed surveys covering primary, inpatient and emergency care, and children's services.</p></sec><sec><st>Results</st><p>Patients under 16 were included in 1/38 national surveys, comprising &lt;0.6% of over 10 million respondents. The majority of young people aged 16&ndash;24 reported a positive experience of NHS care. However, satisfaction was lower than in older adults. 80.7% of 16&ndash;24 year olds reported good emergency department care, compared with 89.2% of older adults (Emergency Department Survey 2008, N=49 646, OR=0.51, 95% CI 0.47 to 0.55, p&lt;0.001). In the Inpatient Survey 2009, 86.5% of 16&ndash;24 year olds reported good care, compared with 92.7% of older adults, (N=69 348, OR=0.51, 95% CI 0.45 to 0.57, p&lt; 0.001). Satisfaction with primary care was reported by 83% of 18&ndash;24 year olds, compared with 90% of older adults (GP Patient Survey 2009&ndash;10 (N=2 169 718, OR=0.52, 95% CI 0.51 to 0.53, p&lt;0.001). Young people also reported a poorer experience than older adults for their perceived involvement in care, having confidence and trust in their doctor and being treated with respect and dignity.</p></sec><sec><st>Conclusions</st><p>Despite the current focus on services for young people and the importance of patients' views in improving services, the voice of under 16s is not included in most national surveys. Despite high levels of overall satisfaction, young adults report a poorer experience of care than older adults.</p></sec>]]></description>
<dc:creator><![CDATA[Hargreaves, D. S., Viner, R. M.]]></dc:creator>
<dc:date>2011-09-19T18:01:59-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300603</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300603</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Press releases, Adolescent health, Child health]]></dc:subject>
<dc:title><![CDATA[Children's and young people's experience of the National Health Service in England: a review of national surveys 2001-2011]]></dc:title>
<prism:publicationDate>2011-09-19</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2010.202069v2?rss=1">
<title><![CDATA[Interferon-{gamma} release assay for the diagnosis of tuberculosis in children]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2010.202069v2?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>To compare the QuantiFERON-TB GOLD In Tube test (QTF) and the tuberculin skin test (TST) in children.</p>
</sec>
<sec><st>Methods</st>
<p>A prospective study was carried out in nine hospitals in Madrid, Spain. TST and QTF were performed in immigrants, tuberculosis (TB) contacts and patients with TB disease (TBD).</p>
</sec>
<sec><st>Results</st>
<p>459 children were included. Disagreement between the tests was more frequently observed among latent tuberculosis infection (LTBI) cases (54%; 38/70) than in non-infected or TBD cases (0.8%; 3/369) (p&lt;0.01). There were more BCG-vaccinated children among LTBI cases with negative QTF (76%) than among LTBI cases with positive QTF (40%) (p&lt;0.001). Agreement between tests in BCG-vaccinated children was lower than in non-vaccinated cases (p&lt;0.05). Tests in TB exposed patients showed better agreement than in non-exposed children (p&lt;0.05).</p>
</sec>
<sec><st>Conclusions</st>
<p>Agreement of both tests was excellent in TBD cases, non-vaccinated children and non-infected patients. A significant number of QTF negative results were observed among LTBI cases, especially in BCG-vaccinated children. Agreement was better in exposed children.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Mendez-Echevarria, A., Gonzalez-Munoz, M., Mellado, M. J., Baquero-Artigao, F., Blazquez, D., Penin, M., Navarro, M. L., Saavedra-Lozano, J., Teresa Hernandez-Sampelayo, M., Gonzalez-Tome, I., Calvo, C., Ruiz, M., Tomas Ramos, J., Guillen, S., Velazquez, R., Perez, B., Martinez, J., Perez, E., ; Spanish Collaborative Group for the Study of the QuantiFERON-TB GOLD Test in Children]]></dc:creator>
<dc:date>2011-08-09T01:07:24-07:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.202069</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2010.202069</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Child health]]></dc:subject>
<dc:title><![CDATA[Interferon-{gamma} release assay for the diagnosis of tuberculosis in children]]></dc:title>
<prism:publicationDate>2011-08-09</prism:publicationDate>
<prism:section>Short report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/archdischild-2011-300294v1?rss=1">
<title><![CDATA[Quality of published case reports on adverse drug reactions in children]]></title>
<link>http://adc.bmj.com/cgi/content/short/archdischild-2011-300294v1?rss=1</link>
<description><![CDATA[ <p>In 2007, the International Society for Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP) released guidelines for publishing case reports on adverse drug reactions (ADRs). These guidelines describe what authors should consider when constructing an ADR case report for publication in terms of key information about the affected patient, administered drugs, reported reaction, causality assessment and implications for clinical practice.<cross-ref type="bib" refid="R1">1</cross-ref></p> <p>In this study, we assessed the adherence to ISPE/ISoP guidelines for ADR case reports of paediatric patients published from January 2008 to December 2010 and entered in Pfizer's safety database. We also developed a case report quality score by assigning a value of 1 or 0 based on the presence or absence of the ISPE/ISoP items, respectively. A cut-off score was established at the 75th percentile for adjudicating reports that were acceptably complete. All reports were independently assessed by two physicians; in case of disagreement, the...]]></description>
<dc:creator><![CDATA[Impicciatore, P., Iato, V., Sevoz, V., Mucci, M.]]></dc:creator>
<dc:date>2011-07-25T21:05:44-07:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300294</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;archdischild-2011-300294</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Quality of published case reports on adverse drug reactions in children]]></dc:title>
<prism:publicationDate>2011-07-25</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2010.195180v1?rss=1">
<title><![CDATA[Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2010.195180v1?rss=1</link>
<description><![CDATA[
<p>Chronic lung disease of prematurity (CLD) remains a major cause of morbidity and mortality in preterm infants. <I>Ureaplasma</I> has received intermittent attention over the last two decades as a possible contributory factor. In addition, pulmonary inflammation is associated with the development of CLD. The macrolide azithromycin provides an attractive option to determine if it can decrease the development of CLD as it has both anti-inflammatory and anti-infective properties. In this article, the authors review the evidence for the role of <I>Ureaplasma</I> in the development of CLD and the obstacles faced in the development of a drug before it reaches clinical practice.</p>
]]></description>
<dc:creator><![CDATA[Turner, M. A., Jacqz-Aigrain, E., Kotecha, S.]]></dc:creator>
<dc:date>2011-06-22T04:16:45-07:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.195180</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2010.195180</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Immunology (including allergy), Drugs: infectious diseases, Pneumonia (infectious disease), TB and other respiratory infections, Child health, Infant health, Neonatal health, Pneumonia (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development]]></dc:title>
<prism:publicationDate>2011-06-22</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2010.206268v1?rss=1">
<title><![CDATA[Changes in primary care prescribing patterns for paediatric asthma: a prescribing database analysis]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2010.206268v1?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Little is known about the impact of British asthma management guideline revisions. Concerns about the use of high dose inhaled corticosteroids (ICS) in children have resulted in the promotion of add-on therapy.</p>
</sec>
<sec><st>Aims</st>
<p>To assess prescribing patterns of asthma medication in children in the primary care setting.</p>
</sec>
<sec><st>Methods</st>
<p>Retrospective observational study of asthma prescribing in children aged 0-18 years using primary care database from 2001 to 2006.</p>
</sec>
<sec><st>Results</st>
<p>The proportion of children prescribed oral corticosteroids increased significantly (from 6% in 2001-2002 to 16% in 2005-2006, p&lt;0.001), while the proportion of children prescribed an ICS dose of &gt;400 mcg decreased from 16.2% to 11.7% (P&lt;0.001). The proportion of children prescribed an add-on therapy and an ICS dose &gt;400 &micro;g, increased from 38.8 % in 2001-2002 to 61.2% in 2005-2006 (p&lt;0.001).</p>
</sec>
<sec><st>Conclusions</st>
<p>Although adherence with asthma management guidelines is not optimal, this study has identified improved adherence in primary care.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Elkout, H., Helms, P. J., Simpson, C. R., McLay, J. S.]]></dc:creator>
<dc:date>2011-05-19T01:37:53-07:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.206268</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2010.206268</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Child health, Asthma, Drugs: respiratory system]]></dc:subject>
<dc:title><![CDATA[Changes in primary care prescribing patterns for paediatric asthma: a prescribing database analysis]]></dc:title>
<prism:publicationDate>2011-05-19</prism:publicationDate>
<prism:section>Short report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2010.198275v1?rss=1">
<title><![CDATA[Resource and outcome in paediatric diabetes services]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2010.198275v1?rss=1</link>
<description><![CDATA[
<p>The availability of resource (staffing and services) in all 21 paediatric diabetes services in Yorkshire and Humber Strategic Health Authority, UK was surveyed and this information was combined with demographic and clinical data on 2683 children and young people with diabetes (aged 0&ndash;23 years) to assess whether level of resource was associated with glycaemic control (mean HbA1c %). Multilevel modelling and graphical techniques were used to analyse the relationship between resource and outcome for paediatric diabetes services. No services achieved all resource recommendations based on National Institute for Health and Clinical Excellence guidelines, but there was no direct association between level of resource and glycaemic control after controlling for deprivation, age and duration of diabetes. Transitional care, nurse caseload and access to specialist services are not adequately resourced but variation in outcome between services is not accounted for by level of resource.</p>
]]></description>
<dc:creator><![CDATA[Harron, K. L., McKinney, P. A., Feltbower, R. G., Holland, P., Campbell, F. M., Parslow, R. C.]]></dc:creator>
<dc:date>2011-05-09T11:35:05-07:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.198275</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2010.198275</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Resource and outcome in paediatric diabetes services]]></dc:title>
<prism:publicationDate>2011-05-09</prism:publicationDate>
<prism:section>Short report</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2010.206201v1?rss=1">
<title><![CDATA[Do paediatric high dependency units in district general hospitals improve patient care? A local review of children presenting with seizures]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2010.206201v1?rss=1</link>
<description><![CDATA[ <p>Following centralisation of paediatric intensive care, paediatric high dependency units (PHDUs) have been set up in some district general hospitals (DGHs) across the UK as recommended by the Department of Health.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> While children with a variety of acute illnesses are managed in PHDUs, their impact on health outcomes such as quality and cost of care remains unknown.<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref></p> <p>Based on our experience, PHDUs may improve the care of children with an underlying diagnosis of epilepsy who present with seizures. Some of these children require a period of ventilation for airway management, support of breathing or seizure termination. Early extubation in the DGH may prevent transfer to a regional paediatric intensive care unit (PICU) by intensive care retrieval services, provided an appropriate environment for postextubation care such as PHDU is available. Here, we report findings of an audit which suggest that...]]></description>
<dc:creator><![CDATA[Behjati, S., Jamieson, K., Montgomery, M., Patel, N., Jaswon, M.]]></dc:creator>
<dc:date>2011-01-10T00:00:47-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.206201</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2010.206201</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Do paediatric high dependency units in district general hospitals improve patient care? A local review of children presenting with seizures]]></dc:title>
<prism:publicationDate>2011-01-10</prism:publicationDate>
<prism:section>Postscript</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2010.189639v1?rss=1">
<title><![CDATA[Mothers, babies and friendly bacteria]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2010.189639v1?rss=1</link>
<description><![CDATA[ <p>There have been a number of reports recently that mother's breast milk may be a source of beneficial bacteria that colonise her infant's gastrointestinal tract.<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3"></cross-ref><cross-ref type="bib" refid="R4"></cross-ref><cross-ref type="bib" refid="R5"></cross-ref><cross-ref type="bib" refid="R6"></cross-ref><cross-ref type="bib" refid="R7"></cross-ref><cross-ref type="bib" refid="R8"></cross-ref><cross-ref type="bib" refid="R9"></cross-ref><cross-ref type="bib" refid="R10"></cross-ref><cross-ref type="bib" refid="R11"></cross-ref><cross-ref type="bib" refid="R12"></cross-ref><cross-ref type="bib" refid="R13"></cross-ref><cross-ref type="bib" refid="R14"></cross-ref><cross-ref type="bib" refid="R15"></cross-ref><cross-ref type="bib" refid="R16">16</cross-ref> The human gut is the home of a large community of bacteria which plays a part in a range of activities which contribute to our health. Occupying the colon, where their collective number of cells exceeds that of their host by a factor of 10, the &lsquo;gut microbiota&rsquo; enjoy an intimate and mutually beneficial relationship with the multicellular organism they inhabit. With metabolic activities as diverse and complex as those of the liver, they can be considered an organ in their own right.<cross-ref type="bib" refid="R17">17</cross-ref> These &lsquo;friendly&rsquo; bacteria are crucial for the...]]></description>
<dc:creator><![CDATA[Beattie, L. M., Weaver, L. T.]]></dc:creator>
<dc:date>2010-08-24T10:12:24-07:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.189639</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2010.189639</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Mothers, babies and friendly bacteria]]></dc:title>
<prism:publicationDate>2010-08-24</prism:publicationDate>
<prism:section>Leading articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2010.186429v1?rss=1">
<title><![CDATA[Heel blood sampling in European neonatal intensive care units: compliance with pain management guidelines]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2010.186429v1?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>To describe the use of heel blood sampling and non-pharmacological analgesia in a large representative sample of neonatal intensive care units (NICUs) in eight European countries, and compare their self-reported practices with evidence-based recommendations.</p>
</sec>
<sec><st>Methods</st>
<p>Information on use of heel blood sampling and associated procedures (oral sweet solutions, non-nutritive sucking, swaddling or positioning, topical anaesthetics and heel warming) were collected through a structured mail questionnaire. 284 NICUs (78% response rate) participated, but only 175 with &ge;50 very low birth weight admissions per year were included in this analysis.</p>
</sec>
<sec><st>Results</st>
<p>Use of heel blood sampling appeared widespread. Most units in the Netherlands, UK, Denmark, Sweden and France predominantly adopted mechanical devices, while manual lance was still in use in the other countries. The two Scandinavian countries and France were the most likely, and Belgium and Spain the least likely to employ recommended combinations of evidence-based pain management measures.</p>
</sec>
<sec><st>Conclusions</st>
<p>Heel puncture is a common procedure in preterm neonates, but pain appears inadequately treated in many units and countries. Better compliance with published guidelines is needed for clinical and ethical reasons.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Losacco, V., Cuttini, M., Greisen, G., Haumont, D., Pallas-Alonso, C. R., Pierrat, V., Warren, I., Smit, B. J., Westrup, B., Jacques Sizun for the ESF Network]]></dc:creator>
<dc:date>2010-08-24T10:12:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.186429</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2010.186429</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Heel blood sampling in European neonatal intensive care units: compliance with pain management guidelines]]></dc:title>
<prism:publicationDate>2010-08-24</prism:publicationDate>
<prism:section>Original articles</prism:section>
</item>
<item rdf:about="http://adc.bmj.com/cgi/content/short/adc.2009.160853v1?rss=1">
<title><![CDATA[Period problems: disorders of menstruation in adolescents]]></title>
<link>http://adc.bmj.com/cgi/content/short/adc.2009.160853v1?rss=1</link>
<description><![CDATA[
<p>Adolescence is a time of great psychological and physical change. In the UK, girls enter puberty around the age of 10 years with a median age of menarche of 12.9 years; thereafter, it may be several years before regular menstrual cycles are established. Variations in the type and the frequency of periods may create anxiety regarding ill health or serious underlying disorders. With the increase in childhood obesity and subsequent polycystic ovary syndrome, there is a greater awareness and presentation of girls with disorders of menstruation.</p>
<p>This review focuses on normal variations of menses and common pathological causes of menstrual problems, including amenorrhoea, dysmenorrhoea and menorrhagia. Further consideration is given to the variations of presentation of polycystic ovary syndrome. It provides a guide to evaluate the various symptoms, investigations and management options.</p>
]]></description>
<dc:creator><![CDATA[Peacock, A., Alvi, N. S., Mushtaq, T.]]></dc:creator>
<dc:date>2010-06-24T02:47:43-07:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2009.160853</dc:identifier>
<dc:identifier>hwp:master-id:archdischild;adc.2009.160853</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Period problems: disorders of menstruation in adolescents]]></dc:title>
<prism:publicationDate>2010-06-24</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
</rdf:RDF>
